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ABSTRACT
ROLE OF REDOX-SENSITIVE CALCIUM/CALMODULIN-DEPENDENT
PROTEIN KINASE IIα IN ANGIOTENSIN II INTRA-NEURONAL SIGNALING
AND ANGIOTENSIN II-MEDIATED HYPERTENSION
Urmi Basu, Ph.D.
University of Nebraska Medical Center, 2015

Advisor: Matthew C. Zimmerman, Ph.D.

Activation of renin-angiotensin system and elevated levels of circulating and
brain angiotensin II (AngII) has been implicated in the pathogenesis of neurocardiovascular diseases, such as hypertension and heart failure. In central
neurons AngII increases generation of reactive oxygen species (ROS), which in
turn regulates neuronal ion channels. Previous studies have demonstrated that
ion channels can also be regulated by protein kinases, such as calcium
/calmodulin-dependent protein kinase II (CaMKII) as a downstream mediator of
AngII signaling. In the heart, CaMKIIδ undergoes oxidation upon AngII
stimulation and increased pro-oxidant conditions. However, the exact mechanism
by which AngII and ROS regulate CaMKIIα, the major neuronal isoform, in central
neurons is unclear. We hypothesized that overexpression of wild-type CaMKIIα in
neurons exacerbates the AngII-mediated inhibition of neuronal ion channels and
the AngII-induced hypertensive response. Indeed, in mouse catecholaminergic
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(CATH.a) neurons overexpression of wt-CaMKIIα significantly enhanced the
AngII-mediated reduction in K+ current as compared to non-transduced and
adenoviral control vector-transduced neurons. Overexpression of wt-CaMKIIα in
brain subfornical organ sensitized mice to an immediate increase in blood
pressure at an initial subpressor dose of chronic subcutaneous AngII infusion.
We further hypothesized that mutation of redox-sensitive cysteine and
methionine residues at positions 280 and 281 respectively of CaMKIIα will inhibit
the potentiated AngII-signaling in neurons and the rise in blood pressure.
Adenovrius-mediated expression of mut-CaMKIIα in CATH.a neurons resulted in
a significant restoration of the potentiated AngII-mediated K+ current inhibition
observed with wt-CaMKIIα overexpression. Further, mice with mut-CaMKIIα in
the brain were prevented from the initial sensitization mechanism following
subcutaneous AngII infusion and the peak AngII-induced blood pressure was
also significantly attenuated as compared to mice with wt-CaMKIIα
overexpression. Together, these studies indicate that redox-regulation of
CaMKIIα is an important mechanism in AngII-downstream signaling in neurons
and in mediating AngII-induced neurogenic hypertension.
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Chapter I: BACKGROUND

Cardiovascular disease and hypertension

Cardiovascular disease is the major cause of morbidity and mortality worldwide.
The American Heart Association (AHA) reported in 2013 that cardiovascular
disease and particularly heart disease is the leading cause of death specifically
within the United States (1). Cardiovascular disorders include coronary heart
disease (heart attacks), cerebrovascular disease (stroke), raised blood pressure
(hypertension), peripheral arterial disease, congenital heart disease and heart
failure. Hypertension is a key risk factor of cardiovascular disease and according
to World Health Organization (WHO) approximately 17 million deaths each year
are due to cardiovascular disease of which 9.4 million is attributable to
complications of hypertension (2). The increasing occurrence of hypertension
includes a growing geriatric population, and behavioral risk factors, such as
unhealthy diet, lack of physical activity, poor stress management, and the use of
tobacco and alcohol (2). Hypertension is considered as a “silent” invisible killer
which impacts global public health concerns and is in constant progress due to
the growing incidence of diabetes and obesity (2-4). Furthermore, uncontrolled
hypertension is a risk for several cardiovascular disorders, including stroke, heart
failure, coronary artery disease, kidney failure, and peripheral vascular disease
(5).
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Blood pressure regulation and hypertension
Blood pressure is the mean arterial pressure that is monitored and regulated by
physiological mechanisms in the body. It is the force of blood that pushes against
the arterial walls of the arteries as the heart pumps blood to the systemic tissues
of the body. Blood pressure is commonly measured by a stethoscope and a
sphygmomanometer (also referred to as a sphygmometer). It is attached to an
inflatable air-bladder cuff to temporarily restrict blood flow and a mercury or
mechanical manometer measures the pressure. Blood pressure is recorded as
two numbers written as a ratio where the top number is the systolic blood
pressure (SBP) and the bottom is the diastolic blood pressure (DBP). Systolic
blood pressure is recorded when the first heartbeat is detected after releasing the
cuff and represents the pressure in the arteries when the heart muscle contracts.
Diastolic blood pressure is the number recorded when the last heartbeat is
detected after releasing the cuff and represents pressure in the arteries when the
heart relaxes. As per the AHA, the recommendation is for adults to maintain
blood pressure less than 120/80 mmHg (systolic/diastolic) to avoid other
complications associated with hypertension (6-8). Clinically, hypertension is
diagnosed as blood pressure which is consistently greater than 140 mmHg
systolic pressure and 90 mmHg diastolic pressure. Blood pressure between the
healthy and hypertensive range is considered to be prehypertension.
There are two major determinants of blood pressure: the heart’s cardiac
output (CO) and the total peripheral resistance (TPR). Cardiac output is defined
as the direct product of heart rate (HR) and cardiac stroke volume (SV). When
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either HR or SV is high, CO increases. Stroke volume is determined by the
contractility of the heart and how much blood returns to the heart (venous return).
Total peripheral resistance is the resistance on the arteries when the blood flows
and can be regulated by a number of circulating factors, including angiotensin II
(AngII), catecholamines, prostaglandins, direct innervation of specific receptors
(α1 and β2), endothelin, adenosine, nitric oxide and also blood viscosity. Blood
pressure is regulated by both divisions of the autonomic nervous system: the
sympathetic and the parasympathetic nervous system.
Renin-angiotensin System
It has long been established that the renin-angiotensin system (RAS) plays a
critical role in cardiovascular and renal homeostasis and has a central regulatory
role on blood pressure maintenance (9). It is classically described as an
endocrine system and regulates extracellular fluid and electrolyte balance
thereby maintaining cardiovascular homeostasis in the body. The RAS comprises
of several effector peptides that are formed through a series of enzymatic
cleavages. The cascade is initiated when aspartyl-protease renin, secreted from
the juxtaglomerular cells of the kidney cleaves the precursor globulin
angiotensinogen (AGT) to form the decapeptide angiotensin 1-10 (commonly
known as Ang I). Ang I is physiologically inactive but can be cleaved by the
membrane-bound dipeptidyl carboxypeptidase, angiotensin converting enzyme
(ACE), resulting in the formation of the octapeptide, AngII, the primary effector
peptide of the RAS (10). Additionally, AngI can be cleaved by angiotensin
converting enzyme 2 (ACE2) to produce Ang-(1-9), which can subsequently be
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cleaved by ACE to form Ang-(1-7). Alternatively, ACE2 can also act upon AngII
to generate Ang-(1-7).
AngII carries out its function by acting on two major G protein-coupled
AngII receptor subtypes – AngII type 1 receptor (AT1R) and AngII type 2 receptor
(AT2R). The AT1R has a wide tissue distribution with high expression in
vasculature, kidney, adrenal gland, heart and some of the cardiovascular control
brain regions (10-12). It is well recognized that the AT1R subtype mediates most
of the well-known actions of AngII, including increased sympathetic output,
vasoconstriction, release of vasopressin, norepinephrine (NE) and, aldosterone
(13, 14). In addition the AngII-AT1R is also involved in sodium and water

reabsorption in the kidneys, increase in heart rate, and stimulation of thirst and
salt appetite(15) (Figure 1.1). Furthermore, recent studies have also
demonstrated AngII-mediated activation of the immune system, particularly T cell
and cytokine activation, which may act as a positive feedback loop in the
development and maintenance of cardiovascular disease (16). The effects of
AngII via the AT1R are mediated by complex signaling pathways involving
phospholipids (phospholipase C (PLC), PLD, PLA2), induction of gene
transcription (c-fos, c-jun, c-myc), activation of redox mechanisms such as
nicotinamide adenine dinucleotide phosphate (NADPH) oxidases and production
of reactive oxygen species (ROS), and also activation of tyrosine kinases (Src,
JAK-STAT, PI3K)(13, 17-19). In contrast, the AT2R which is highly expressed in
fetal tissue, including fetal aorta, brain, adrenal medulla, kidney, and
mesenchymal layer of the gastrointestinal tract, is involved more in counteracting
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the actions of AT1R and does not have direct regulation on cardiovascular
physiology (10, 20, 21). Furthermore, the AT2R can dimerize with the AT1R and
interrupt the AngII-AT1R-mediated signaling mechanisms (21, 22). Most of the
studies investigating the role of the different AngII receptor subtypes have been
done by using specific receptor agonists and antagonists – for example, a
selective agonist of the AT2R, compound 21, has shown beneficial effects on
cardiovascular function and baroreflex sensitivity(23-25). On the other hand
systemic administration of AT1R antagonist, such as losartan and irbesartan,
lowers blood pressure and improves impaired baroreflex sensitivity in genetically
hypertensive rats (26-29).
In contrast to the “hypertensive axis” of the RAS comprising ACE-AngIIAT1R signaling, Ang-(1-7) binds to Mas receptor (MasR) to induce opposing
effects to AngII-AT1R mechanisms. MasR is primarily expressed in brain and
testis but also in kidney, heart and vessels, and its activation leads to
vasodilation, decreased inflammation, reduction in sympathetic activity,
antifibrotic, antihypertrophic and antithrombotic effects (12, 30, 31). The MasR can
also heterodimerize with the AT1R and thereby antagonize it (32-34). The ACE2Ang-(1-7)-MasR is thereby considered as the “anti-hypertensive axis” of the RAS.
Indeed, studies in the recent past have demonstrated the potential therapeutic
effect of the ACE2-MasR axis on cardiovascular diseases including heart failure
and hypertension (35). Moreover, the nonpeptide orally active MasR agonist AVE
0991 has shown to preserve cardiac function and prevent end-organ damage in
animal models of hypertension (36).
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Although AngII is considered as the primary effector peptide of the RAS,
recent studies have identified some of the AngII metabolites as other active
components of the system. Aminopeptidase A (APA) cleaves the N-terminal
aspartyl residue of AngII resulting in the formation of Ang-(2-8), commonly
referred to as Ang III. Ang III can be further metabolized into Ang-(3-8) (Ang IV)
by aminopeptidase N (APN). Ang III displays comparable affinity to the AT1R and
exerts similar actions as AngII such as aldosterone release and vasoconstriction
(37, 38). APA inhibitors have also shown to attenuate central effects of AngII in

AngII-mediated hypertension model (39).
Numerous studies done over the decades have illustrated the importance
of different RAS components in blood pressure regulation and cardiovascular
homeostasis by using specific pharmacological inhibitors as mentioned above.
The pharmacological blockers were used either to inhibit the formation or actions
of the key mediators of the RAS. In addition to β-blockers, some of the most
widely used drugs in the treatment of hypertension and other cardiovascular
diseases are the ones that inhibit ACE (ACEi) thereby limiting the formation of
AngII or that block the actions of the AngII receptors (ARBs)(40).
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Figure 1.1- Renin-angiotensin system cascade. Abbreviations: ACEangiotensin converting enzyme; ADH – anti-diuretic hormone (also known as
vasopressin); AGT – angiotensinogen; ALD – aldosterone; Ang I – angiotensin I;
AngII – angiotensin II; AT1R – angiotensin type 1 receptor; AT2R – angiotensin
type 2 receptor; CAGE – chymostatin-sensitive angiotensin II-generating
enzyme; MasR – mas receptor; NE – norepinephrine; NEP – neutral
endopeptidase; PEP – prolylendopeptidase; PCP – prolylcarboxypeptidase; tPA
– tissue plasminogen activator
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Brain-angiotensinergic systems and hypertension
The first identification of renin in the brain was made by Ganten et al. and FisherFerraro et al. (41, 42) and this was subsequently followed by identification of the
existence of AngII-processing pathways in the central nervous system (CNS).
The fact that AngII immunoreactivity is detected in the brain after nephrectomy
(43, 44) suggests that the brain RAS is modulated independently of the peripheral

RAS. Central injections of AngII in specific brain regions elicit profound
cardiovascular and drinking response indicating the pivotal role of brain
angiotensinergic mechanisms in cardiovascular control (45). Almost all of the
RAS components have been identified in the CNS, including the enzymes that
are involved in the generation of these effector molecules. For example, AGT,
the primary precursor of AngII is widely distributed in the brain with the highest
expression found in the hypothalamus, mainly the supraoptic nucleus (SON),
paraventricular nucleus (PVN), and preoptic nucleus (46, 47). Interestingly, levels
of renin, the enzyme that cleaves AGT into Ang I, is low in the brain and is
detected in regions similar to AGT in addition to brain stem and cortical regions
(48). However, recent studies have demonstrated the existence of prorenin and

prorenin receptor (PRR) in important cardiovascular control brain nuclei (49).
Non-proteolytic activation of prorenin by binding to the PRR can lead to
increased generation of AngII independent of the renin pathway and neuronspecific knock out of this receptor can attenuate blood pressure in a salt-sensitive
hypertension model where brain AngII levels are increased (50, 51). Several
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biochemical and immunohistochemical studies have found ACE, the enzyme
responsible for the conversion of Ang I to AngII in the basal ganglia, SON, PVN,
nucleus tractus solitarius (NTS) and dorsal motor nucleus of the vagus (52, 53).
These evidences thus suggest that AngII is produced in local tissues in the brain
which is independent of the peripheral RAS.
In addition, systemic AngII can also act upon certain blood brain barrier
(BBB) deficient brain nuclei known as circumventricular organs (CVOs) (54).
These CVOs are present mainly bordering the third and fourth ventricles and are
densely populated with fenestrated capillaries for high permeability (55). Among
the CVOs, the subfornical organ (SFO), organum vasculosum of the lamina
terminalis (OVLT) and area postrema (AP) (Figure 1.2) are the key
cardiovascular control brain regions and express high levels of the AT1R (55, 56).
The CVOs receive inputs from systemic baroreceptors and chemoreceptors and
in turn send out neural projections to some of the downstream extensive neural
network involved in maintaining various cardiovascular responses, vasopressin
release, and autonomic responses (54, 57). More specifically, anatomical studies
with anterograde tracing markers have identified projections from SFO in the
forebrain to SON and PVN (54, 57, 58). Additionally, neurons from the
parvocellular region of the PVN send axons to centers in the rostral ventrolateral
medulla (RVLM) and intermediolateral cell column of the spinal cord, which are
also important centers of sympathetic outflow and baroreceptor reflex regulation
(54, 57, 58) The importance of CVOs in brain angiotensinergic signaling have

been demonstrated in studies whereby the AngII-induced activation of PVN
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neurons is greatly attenuated by electrolytic lesion of the SFO in rats (59-61).
Lesioning the SFO also attenuates mean arterial pressure in an AngII-salt
sensitive hypertension model (62). In addition, central injection of AngII directly
into the SFO increases pressor, bradycardic and dipsogenic response (62, 63).
Electrophysiological studies show that intravenous administration of AngII
increases excitability of SFO neurons via an AT1R-mediated mechanism which
inhibited transient outward potassium current and increased intracellular calcium
(63-65).Furthermore, intracerebroventricular (ICV) infusion of losartan reduces
AT1R mRNA and immunoreactivity in the SFO of heart failure animals (66). ICV
infusion of losartan also reduces elevations in metabolic rate in a
deoxycorticosterone acetate-salt (DOCA-Salt) hypertension model indicating the
importance of brain angiotensinergic signaling in various animal models of
hypertension (67). In addition to the SFO, destruction of the AP eliminates the
pressor effect of AngII infusion into the vertebral arteries (68). Similar to the SFO,
the central AngII-mediated dipsogenic and pressor effects can be blocked by
lesion of the OVLT (68).
Selective overexpression of other components of the RAS, such as ACE2,
in the brain can attenuate neurogenic hypertension by preventing decrease in
spontaneous baroreflex sensitivity and parasympathetic tone (69, 70). ACE2
overexpression in the brain also causes upregulation of the AT2 and MasR (69)
thus shifting the balance between the “hypertensive” and the “anti-hypertensive”
axis of the RAS. Ang III, another bioactive peptide of the RAS has similar affinity
as AngII for AT1R in the brain and is involved in blood pressure control and body
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fluid and electrolyte balance (38, 71). Both AngII and Ang III in the brain are
involved in increasing sympathetic nerve activity, inhibition of baroreflex
sensitivity in the NTS and release arginine vasopressin (AVP) from the posterior
pituitary. As such, studies by Marc et al. has identified inhibitors of APA, enzyme
responsible for the generation of Ang III from AngII, to therapeutically target the
brain RAS in hypertension (39). Together, these studies clearly demonstrate the
significance of the brain angiotensinergic mechanisms in the regulation of neurocardiovascular function and dysregulation in their signaling pathways can lead to
diseases, including hypertension and heart failure.
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Figure 1.2. Cardiovascular regulatory nuclei involved in brain
angiotensinergic signaling mechanisms. Modified from Davisson and
Zimmerman (72)
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Angiotensin II intra-neuronal signaling mechanisms
The AngII intra-neuronal signaling cascade involves a number of key mediators,
including reactive oxygen species (ROS), protein kinases and phosphatases, ion
channels, transcription factors, and matrix metalloproteinases (MMPs). The
localization of the AngII receptor subtypes in the brain is quite different. For
example, most of the AT1Rs are concentrated in the SFO, PVN, SON, and in the
nuclei of the brainstem, whereas the AT2Rs are found in the thalamus,
cerebellum, locus ceoruleus and particularly in the inferior olivary nucleus
reflecting the different functional role of each of these receptor subtypes (13, 73).
Numerous studies so far have well documented the AngII intracellular signaling
mechanisms in the periphery (13, 74). In contrast, the neuronal signaling
mechanisms mediated by AngII in the brain are still not fully understood. In the
peripheral tissues and cells, AngII initiates a number of diverse signaling
pathways via the AT1R, such as stimulation of phosphoinositide (PI) hydrolysis
by coupling the AT1R to Gq or Gq-like protein. This is followed by generation of
inositol (1,4,5)-triphosphatase (IP3), with subsequent increase in intracellular
Ca2+ and diacylgylcerol (DAG)-mediated increase in protein kinase C (PKC)
activity (17, 74). Interestingly, AT1R coupling to the Gi protein can inhibit adenylyl
cyclase depending on the cell and type of tissue. AT1R activation by AngII can
also stimulate Ras/Raf/mitogen activated protein (MAP) kinase and JAK
(Janus/Kinase) STAT (signal transducers and activators of transcription)
signaling pathways (17, 74). Importantly, studies using cultured neurons from rat
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brain have demonstrated that a number of these AT1R-mediated AngII signaling
occurs in the CNS. Activation of AT1Rs in the median eminence as well as in
cultured neurons leads to a stimulation of PI hydrolysis causing IP3 generation
and increases in [Ca]i and activation of PKC (13, 14, 75, 76). Furthermore
increased concentration of [Ca]i activates downstream signaling molecules, such
as calcium/calmodulin-dependent protein kinase II (CaMKII). The AngII-AT1R
mediated PI hydrolysis is also observed in a neuroblastoma glial cell line (NG
108-15). The Ras/Raf pathway and activation of MAP kinases by AngII by acting
on the AT1R is also documented in cultured neurons. Increased MAP kinase
activity mediates the known stimulatory effects of AngII on neuronal NE synthesis
via the induction of Fos and Jun proteins (14, 77, 78). Furthermore, studies by
Sumners and Raizada have demonstrated major short term effects of AngII on
neuronal ion channel current and neuronal firing that is also mediated via the
AT1R. For example, AT1R stimulation leads to an increase in total neuronal Ca2+
current (ICa) and also causes inhibition of delayed rectifier K+ current (IKV) and the
A type transient K+ (IA) current in primary neurons from rat hypothalamus and
brain stem and also in a mouse catecholaminergic neuronal cell line (CATH.a
neurons) (75, 79). These currents are the basis of neuronal action potentials and
therefore, changes in Ca2+ and K+ ion channel current leads to an increase in
neuronal firing frequency ultimately causing neuronal excitation. Involvement of
signaling molecules, such as PKC and CaMKII have been investigated in the
regulation of these ion channel currents by AngII by using specific inhibitors,
such as calphostin C to inhibit PKC and KN-93 to block CaMKII activity (80, 81).
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Inhibition of either PKC or CaMKII attenuates the AngII-mediated reduction in IKV
and the increase in neuronal firing frequency (80, 81). However, the precise
mechanism by which AngII regulates PKC and CaMKII thereby modulating
neuronal ion channels is not yet fully elucidated.
Similar to the AT1R, the AT2R-mediated intracellular signaling also
modulates a variety of signaling molecules. In the heart, kidney, and cultured
neurons, AT2R activation causes stimulation of phospholipase A2 (PLA2) activity
(13). In neurons, this increase in PLA2 activity generates arachidonic acid which

can then lead to regulation of neuronal ion channels (13). Several studies have
also shown that in neurons, AngII by acting on the AT2R can activate
serine/threonine phosphatase type 2A (PP2A) and in turn inhibit MAP kinase
activity (78). Selective activation of the AT2R causes potentiation of neuronal IKV
and IA, an effect opposing to the AT1R. AT2R does not seem to have any
regulatory role on ICa in cultured neurons, but inhibits T-type Ca2+ current in
undifferentiated NG108-15 neuroblastoma x glioma cells (82). AngII-mediated
AT2R activation thereby leads to a decrease in neuronal excitability.
To better understand AngII-intraneuronal signaling in the pathogenesis of
neuro-cardiovascular disorders, several in vivo and in vitro experimental models
have been established. Numerous studies have shown that acute stimulation of
cultured neurons with AngII results in rapid increase in intracellular calcium,
inhibition of outward potassium current (IKv), and an increase in neuronal firing
(80, 81, 83, 84).In addition, chronic stimulation (i.e. hours to days) of AngIIsensitive cultured neurons leads to alterations in the expression of angiotensin

16

receptors, potassium channel proteins, and transcription factors (85, 86).
Studies from these chronic AngII stimulation studies concluded that these events
mimic the AngII neuronal signaling occurring in vivo in case of disease models,
such as hypertension and heart failure where AngII levels are chronically
elevated (87-89). However, one limitation of these in vitro studies has been the
lack of evidence of chronic AngII stability in neuronal cell culture medium
following a single administration of AngII.
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Figure 1.3. Angiotensin II-intraneuronal signaling mechanisms in central
neurons. Abbreviations: AT1R – Angiotensin II type 1 receptor; ROS – reactive
oxygen species; CaMKII – calcium/calmodulin-dependent protein kinase II; PKC
– protein kinase C; SNA – sympathetic nerve activity; MAP – mean arterial
pressure
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Reactive oxygen species in the central nervous system

Excessive activation of brain RAS or overproduction of AngII induces
cardiovascular malfunctions (87). One of the most promising concepts that
emerged during the last decade is AngII-mediated generation of reactive oxygen
species (ROS) and activation of redox-dependent signaling cascades in the brain
(84, 90). ROS are species of oxygen produced by all aerobic cells and are in a
highly reactive state than molecular oxygen. Although they are best known for
their role in host defense mechanisms (91, 92), ample evidences demonstrate
ROS, primarily superoxide (O2-) and hydrogen peroxide (H2O2) as key signaling
molecules following stimulation of various plasma membrane receptors (93-95).
Imbalance between ROS production and the ability of different scavenging
systems to detoxify the reactive intermediates plays a critical role in neural
mechanism of hypertension and heart failure (89, 96, 97). In the cells, ROS are
mainly generated from incomplete reduction of molecular oxygen through
enzymatic reactions involving NADPH oxidase (NOX) (98, 99) and xanthine
oxidase (95, 100, 101), mitochondrial electron transport chain (ETC) (102-104),
uncoupling of nitric oxide synthases (105), and through cyclo-oxygenases,
lipoxygenases, or cytochrome P450 reductases (95, 106). In the vasculature,
Griendling and colleagues were the first to demonstrate that AngII activates NOX
via the AT1R and this activation causes increase in intracellular O 2- formation
which can lead to endothelial dysfunction and the pathogenesis of AngII-induced
hypertension (107, 108). In the CNS, AngII generates ROS, particularly O2- and
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H2O2 from two major sources – NOX and the mitochondrial ETC. Additionally,
activated proinflammatory cytokines can also mediate AngII-induced ROS
production in the brain (56, 109). Accumulating evidence suggests that AngII
activates AT1R in neurons of major cardiovascular control brain regions, such as
the SFO, PVN and RVLM resulting in increased ROS levels which contribute to
the increase in neuronal activation and subsequent stimulation of the
sympathetic nervous system (97, 109). In addition, AngII reduces activities of
Complexes I, II and III of the mitochondrial ETC, causing a suppression of
electron transfer capacity between the complexes thus leading to electron
leakage and generating increased O2- and H2O2 (103). Importantly, the
vasopressor, bradycardic and dipsogenic responses by intracerebroventricular
(ICV) injection of AngII is mediated, at least in part, by O2- in CVOs, such as the
SFO (110). In the SFO, AngII leads to the increased production of O2- and
removing O2- by specific antioxidants in the SFO abolishes the cardiovascular
and dipsogenic responses to central AngII (90). The primary scavenger of O2- is
the superoxide dismutase (SOD). SOD catalyzes the dismutation of O2- to H2O2
and oxygen and is endogenously expressed as three different proteins: 1)
copper/zinc SOD (CuZnSOD or SOD1), which is primarily localized in the
cytoplasm, but also present in the mitochondria and nucleus; 2) manganese SOD
(MnSOD or SOD2), which is strictly localized in mitochondrial matrix; and 3)
extracellular SOD (ecSOD or SOD3), which is found extracellular. Adenovirusmediated overexpression of CuZnSOD in the SFO also prevents hypertension in
chronic peripheral AngII-infused mice (90). The importance of NOX enzymes in
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mediating the full vasopressor effects of brain AngII in the SFO has been
illustrated (111, 112) by using adenoviral vectors encoding small interfering RNA
to selectively silence NOX2 and NOX4, the two NOX isoforms in the brain.
Interestingly, silencing NOX2 alone and not NOX4, significantly attenuates the
central AngII-induced drinking responses. The differential role of these two NOX
enzymes in mediating the central AngII responses can be due to their different
subcellular localizations in neurons. For example, NOX2 resides primarily in the
plasma membrane, although it has not been fully elucidated in central neurons
(113, 114). In contrast, recent study from our lab has demonstrated NOX4 to be

localized in the mitochondria in CATH.a neurons (115). Furthermore, an important
downstream cellular mechanism induced by O2- is the influx of intracellular Ca2+
as seen in neuroblastoma Neuro 2A cells, which can be inhibited by adenoviralmediated expression of a dominant –negative isoform of Ras-related C3
botulinum toxin substrate 1 (Rac1) (AdN17Rac1), a major component of NOX
complex formation and activation (84). In addition, few studies suggest that ROS
derived from NOX enhances nerve traffic in the SFO-PVN axis (116). Notably,
Erdos et al have shown that ICV injection of AngII increases O 2- production both
in the SFO and PVN and this increase in O2-is attenuated by a NADPH oxidase
inhibitor, apocynin (117). Importantly, the increase in AT1R and ACE mRNA in the
PVN by ICV infusion of aldosterone is blocked by concomitant infusion of tempol,
an SOD mimetic (118). Furthermore, in a model of 2-kidney-1-clip (2K1C)
hypertension, the large increases in cardiac sympathetic activity, baseline renal
sympathetic nerve activity and mean arterial pressure due to microinjection of
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AngII into the PVN is abolished by pretreatment with tempol or apocynin (119).
Microinjection of tempol into the PVN also reduces high blood pressure and
sympathetic activity of renovascular hypertensive rats (120, 121). Gene
expression of NOX subunits, such as p47phox and gp91phox as well as AT1Rs
is also increased in the PVN of those rats (121-123). Recent studies by Braga and
colleagues have shown that overexpression of CuZnSOD into the PVN prevents
the elevation of O2- and the hypertensive response in the 2K1C hypertension
model (122). Similar to the SFO and the PVN, the RVLM has also been
recognized as one of the important brain sites for the accumulation of AngIIinduced O2- and its impact on hypertension (124, 125). The RVLM receives inputs
from the SFO and PVN forming the so-called SFO-PVN-RVLM pathway and
contains bulbospinal neurons that are major inputs to the preganglionic neurons
of the sympathetic nervous system (116, 126-128). It is densely populated with the
AT1R (129) and pharmacological blockade of the AT1R attenuates the pressor
response induced by AngII-microinjected into the RVLM of rabbits (130). In a slow
pressor AngII hypertension model as well as in a 2K1C model, increased levels
of O2- have been demonstrated in the RVLM along with an increase in
sympathetic nerve activity and overexpression of CuZnSOD specifically in the
RVLM attenuates both the accumulation of O2- and the sympathoexcitation (120,
121, 124). In SHRs the MnSOD levels in the RVLM are found to be decreased
(96). The AT1R mRNA expression as well as the NADPH oxidase subunits is

increased in the RVLM of 2K1C rats (120, 124). Injection of tempol into the RVLM
has been documented to decrease blood pressure and renal sympathetic activity
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in 2K1C hypertensive rats (120). Additionally, overexpression of MnSOD in the
RVLM inhibits the cardiovascular responses to AngII microinjected into the RVLM
and also reduces sympathoexcitation and hypertension in SHRs. These studies
therefore implicate the importance of ROS in the brain in different models of
hypertension (131).
Several studies suggesting the role of brain ROS in mediating the
pathogenesis of cardiovascular disorders has been done by using specific ROS
scavengers, such as SOD. In addition to neurons in the brain, AngII can also
cause O2- generation from NOX enzymes in microglial cells (132, 133). Recent
studies have also put forward a feed forward mechanism between NOX and
mitochondria and the idea of a ROS-induced-ROS mechanism (134, 135). These
studies suggest that AngII activates NOX leading to increases in intracellular
Ca2+ concentration which can then be taken up by the mitochondria thus
generating mitochondrial ROS. Indeed studies showing that knockdown of the
p22phox subunit of NOX attenuates the AngII-induced O2- and H2O2 production
in the mitochondrial fractions isolated from the RVLM (103).
One of the major targets of ROS are ion channels and numerous
evidences support the hypothesis that AngII-induced sympathoexcitation is
mediated, atleast in part, by redox modulation of ion channels. The two important
ion channels that play crucial role in action potential generation and neuronal
excitability and can also be regulated by ROS, either directly or indirectly, are the
Ca2+ and K+ channels (79). Evidence from both in vivo and in vitro studies
suggest that the AngII-mediated modulation of Ca2+ and K+ channels involves
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ROS derived from NOX enzymes (84, 136)as well as mitochondrial sources (83).
These studies also suggest a potential role of PKC and CaMKII in the regulation
of these channels. Importantly inhibiting PKC and CaMKII by calphostin C and
KN-93 respectively (80) in primary neurons cultured from rat hypothalamus and
brainstem and scavenging superoxide by either CuZnSOD or MnSOD abolishes
the AngII-mediated reduction in neuronal K+ current (83). Another class of protein
kinases that are known to be redox-regulated and important in cardiovascular
pathogenesis is the MAPK family of proteins. In the brain, redox activation of
MAPK is involved in the AngII-mediated hypertension and heart failure (137,
138). It is well recognized that in the RVLM, AngII via the AT1R-dependent
activation of PKC-NOX-ROS signaling cascade triggers the activation of MAPKs,
particularly p38MAPK and extracellular signal-regulated kinase (ERK) (139, 140).
The activation of p38MAPK pathway in turn mediates the short-term pressor
response of AngII by potentiating the glutamatergic neurotransmission in the
RVLM (139). On the other hand, activation of ERK results in the long-term
pressor response to AngII by upregulating the AT1R mRNA expression (141).
The AngII-ROS-p38MAPK/ERK pathway in the RVLM is also implicated in the
hypertensive phenotype in stroke-prone SHRs (142). In rats with CHF, AngII
triggers the activation of ERK and c-Jun N terminal kinase (JNK) via ROS which
contributes to the upregulation of AT1R and sympathoexcitation (143, 144).
Furthermore, it has been reported in mouse CATH.a neurons, the AngIImediated inhibition of voltage-gated K+ channel expression is dependent on the
AT1R-ROS-p38MAPK signaling pathway (13, 14). In addition, serine/threonine
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protein kinases, such as Akt and Rho are also thought to be redox-sensitive and
are active players in the pathogenesis of cardiovascular disorders (145-147).
These studies confirm the role of ROS as key intermediates in AngII intraneuronal signaling and establish O2- as a sympatho-excitatory molecule in the
brain involved in the cardiovascular complications association with hypertension
and heart failure.
However, although O2- seem to be the major ROS molecule in AngII-redox
signaling mechanisms, evidences also point out a potential role of H 2O2 in some
of the cardiovascular effects mediated by AngII. For example, in stroke-prone
SHR, administration of catalase, the H2O2 scavenging enzyme, into the RVLM
reduces the elevated levels of ROS (131). Catalase expression is also found to
be low in the RVLM of SHRs and overexpression of catalase results in prolonged
hypotension (96). In contrast, the H2O2 generated by dismutation of O2- by
CuZnSOD in the PVN does not play a role in the manifestation of
sympathoexcitation associated with myocardial infarction-induced heart failure
(148). Since catalase is primarily present in the peroxisomes and is not

responsible for reducing H2O2 levels in different subcellular compartments,
therefore, additional studies with other H2O2 removing enzymes, such as
glutathione peroxidase (GPx) and peroxiredoxins (Prx) are required to confirm
the role of H2O2 in mediating AngII-induced neurocardiovascular disorders.
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Protein thiol oxidation in signaling and pathophysiological responses

Elevated levels of ROS contribute to the adverse outcomes of many
cardiovascular pathogenesis, including atherosclerosis, hypertension, heart
failure, diabetes, cardiac hypertrophy and myocardial infarction (106, 149, 150).
Increased production of oxidants, reduced nitric oxide (NO) bioavailability and
decreased antioxidant defense mechanisms in specific organs are involved in
these diseases. In many of these pathological models, in addition to ROS,
excessive generation of reactive nitrogen species (RNS) is also involved thus
leading to increased oxidative and nitrosative stress (151, 152). These excess
oxidants not only affect cellular components, such as membrane lipids and
nucleic acids (153, 154) but can also act as second messengers leading to posttranslational modifications (PTMs) of proteins thus altering cellular homeostasis.
Different amino acids that make up a protein differ greatly in their susceptibility to
get oxidized; however, the two most common PTMs of proteins occur in their
sulfur-containing amino acids – cysteine and methionine (155, 156). Inside the
cell, the cytoplasm is in a highly reducing environment and the protein cysteines
are maintained in their thiol (-SH) or thiolate (-S-) state. This reducing
environment is mainly due to the presence of the most abundant low-molecularweight thiol buffer glutathione (GSH). GSH is a cysteine-containing tripeptide
(glutamate-cysteine-glycine) and is present in millimolar concentrations inside the
cell (156-158). In addition to GSH, there are also a variety of reductive enzymatic
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pathways to remove any disulfide bond formation. These include the ubiquitous
disulfide reductase, thioredoxin (Trx), which reduces oxidized protein substrates
by using electrons derived from NADPH via its reactivating enzyme, thioredoxin
reductase (TR), and glutaredoxin (Grx), which is reduced by GSH, which in turn
is reduced by NADPH-dependent glutathione reductase (GR) (157, 159).
However, under oxidative and/or nitrosative stress conditions the cysteine thiol
groups of proteins are particularly susceptible to oxidation by ROS/RNS and
other electrophilic molecules. The protein thiols not only function in normal
cellular signaling but can also undergo irreversible oxidation in aging and disease
conditions thus changing protein function. The reactivity of most protein thiols is
determined by its pKa (the acid dissociation constant) and at intracellular pH
protein thiols have a pKa of approximately 8.5 which makes them less reactive
(156, 157, 160). However, under certain local charge environments protein thiols

can have a lower pKa and may exist as thiolate anions (cysteine-S-) at
physiological pH thus making them more susceptible to oxidation to ROS/RNS.
One such product of H2O2 oxidation is sulfenic acid (RSOH), which is unstable
and can undergo further oxidation to generate more stable derivatives, such as
sulfinic acid (RSO2H) or sulfonic acid (RSO3H), or react with another thiol to yield
inter- or intra-protein disulfides (PrSSPr, PrSSPr’) (157). Importantly, protein
disulfides, nitrosothiols, sulfenic acid and, in some cases sulfinic acid are
reversible thus providing a mechanism of cell signaling regulation by reversible
changes in protein function (160, 161). On the other hand, oxidation of sulfinic acid
to sulfonic acid is irreversible and therefore the modified protein should either be
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degraded or re-synthesized to restore their normal cellular levels and protect
against oxidative damage (161). Additionally, cysteine residues can also be
modified by RNS, such as NO to yield an S-nitrosothiol (R-SNO), and by
peroxynitrite (ONOO-) to form S-nitrothiol (R-SNO2) (158, 162). As compelling
evidences suggest the importance of regulation of protein function by thiol
modifications, there have been tremendous efforts to develop methods to
determine which proteins, and which amino acid residues within them are most
reactive and also detect the specific thiol modifications. So far, mass
spectrometry and proteomics approaches along with other free thiol labeling
techniques are being utilized to accurately identify thiol modifications (163, 164).
The other sulfur-containing naturally occurring amino acid which is
sensitive to oxidation is methionine. Due to the chiral nature of the sulfur atom in
methionine, both free and protein-based methionine residues can undergo
oxidation by ROS to form a mixture of two diastereomers, methionine-S-sulfoxide
and methionine-R-sulfoxide (165). In the presence of a strong oxidant met
sulfoxide can be further oxidized to methionine sulfone (MetO2) which can lead
to many pathophysiological consequences (166). Similar to cysteine, oxidation of
methionine can also lead to significant alterations of protein structure and
function. As a means to counteract the methionine oxidation, methionine
sulfoxide reductases (Msrs) have evolved as a reductase system in most
organisms, including anaerobic organisms (167). Interestingly, in order to have a
complete reduction of both methionine-(R,S)-sulfoxide residues in proteins two
specific Msr isoforms have evolved – MsrA and MsrB. MsrA is specific for the
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reduction of met-S-sulfoxide while MsrB acts only on met-R-sulfoxide (167-169).
MsrA reduces both free and protein-based met sulfoxide and can also reduce
other methyl sulfoxide compounds, such as dimethyl sulfoxide and sulindac (170).
In contrast, MsrB has a very low activity towards free met sulfoxide and only acts
efficiently on peptidyl met sulfoxide (170). In mammals, a single MsrA gene
encodes for the MsrA protein and contains a mitochondrial signal peptide at the
N-terminus. However, subcellular localization studies in rat and mouse have
shown MsrAs are also present in the cytosol. The MsrB proteins are found in
different cellular compartments and is encoded by three MsrB genes (B1-B3).
The different subcellular localizations of MsrA and MsrB suggest that the met
sulfoxide reduction system is maintained in different compartments of the
mammalian cell to protect against met oxidation (165, 167).
Several studies have investigated the role of cysteine and met oxidation in
target molecules in different experimental systems. For example, reversible
oxidation of a specific cysteine residue in the amino-terminus of the voltagedependent K+ channel (Kv1.4) channel (171) or its associated β subunits (172)
has shown to modulate the N-type inactivation of this channel. In the brain,
glutamate and H+ sensitivity of the NMDA receptors is also regulated by
oxidation of two cysteine residues in NR1 subunits (173). In addition to ion
channels, a number of protein kinases, phosphatases and transcription factors
are also modulated by ROS and/or RNS. One such example is the redox
regulation of different receptor tyrosine kinases (RTKs) that play an important
role in signal transduction pathways by the recognition and response to stimulant
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binding. Once activated by ligand binding, the RTKs can relay its signal through
downstream non-receptor kinases to mediate several biological processes (174).
Finkel and colleagues in their landmark study have showed that the plateletderived growth factor (PDGF)-induced H2O2 production has downstream effects
on global tyrosine phosphorylation, activation of MAPK pathways, DNA synthesis
and chemotaxis (175). The other RTK, epidermal growth factor (EGF) also
induced increase in ROS levels upon receptor binding (176). Further, inhibition of
ROS production blocked the tyrosine signaling triggered by these RTKs
stimulation. In addition, apoptosis signaling kinase 1, PKC, protein kinase A
(PKA) has also been shown to be regulated by redox-based mechanisms in
different signaling pathways (174, 177).
Redox sensitivity of protein phosphatases, particularly the protein tyrosine
phosphatases (PTPs) such as PTP1B, low molecular weight PTP (LMW-PTP),
SH2 domain containing PTPs (SHP-1 and SHP-2) has been well described (178).
The pKa of the catalytic site cysteine of many PTPs is around 6, which makes
them extremely reactive and forms thiolate anions at physiological pH. This
reactive thiol group not only makes them highly susceptible to oxidation but is
also essential for the catalytic mechanism of these PTPs (178). The
serine/threonine protein phosphatases, such as protein phosphatase 2A (PP2A),
has also been shown to be regulated by H2O2 and glutathionylation (179, 180) and
disulfide cross-linking of the catalytic subunit of PP2A with other proteins in the
brain along with the formation of an intramolecular disulfide bond within PP2A
leads to PP2A inhibition in the brain (180).
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Figure 1.4. Thiol-based oxidation of cysteine residues: role of reactive
oxygen species as signaling intermediates (157)
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Redox regulation of CaMKII and its role in AngII signaling pathways

The family of multifunctional calcium/calmodulin (Ca2+/CaM)-dependent protein
kinases (CaMKs) including CaMKI, CaMKII and CaMKIV modulate many of the
cellular responses to Ca2+. These downstream effector molecules translate and
co-ordinate the dynamic second messenger, Ca2+, into appropriate cellular
responses by a highly specific and reversible phosphorylation of a number of
substrate proteins in their serine or threonine residues. This family of protein
kinases has both common as well as unique features with respect to their
structure, regulation and activation. The CaMKII is responsible for the coupling of
Ca2+ increase to ion channel activation (181), gene transcription (182),
neurotransmitter synthesis and release, cytoskeletal organization and apoptosis
(183). It should be noted that different functions of CaMKII are mediated by a

family of CaMKII isoforms derived from four closely related yet distinct genes (α,
β, γ and δ). CaMKII is highly enriched in the brain with the brain specific α (50
kDa) and β (60 kDa) isoform constituting upto 2% of the total protein in the
hippocampus of rodents and upto 1% of the total protein in the forebrain itself.
Furthermore, in forebrain homogenates 19-37 µM concentration of CaMKIIα has
been estimated in the cytosol. CaMKIIδ and γ isoforms are abundantly expressed
throughout the body with the δ isoform predominantly found in the heart. Purified
brain CaMKII has a molecular weight of approximately 460000 – 654000 Da and
is composed of 8-12 subunits. Both heteromultimers and homomers of CaMKIIα
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have been identified from rat forebrain. The CaMKII is a multi-subunit
holoenzyme containing three key domains: the association domain, which directs
multimeric assembly, the regulatory domain, which controls enzyme activation
and autoinhibition, and the catalytic domain, which is responsible for the kinase
function of CaMKII. Under resting conditions CaMKII is maintained in an
autoinhibited state by the autoregulatory domain that acts as a pseudosubstrate,
preventing the binding of substrates to the catalytic domain. The binding of
Ca2+/CaM induces a conformational change in CaMKII that relieves the
autoinhibitory effect of the regulatory domain and exposes the substrate binding
site, thus activating the enzyme. One of the common features of all the CaMKII
isoforms is the presence of autophosphorylation sites within the autoregulatory
region, which is Thr286 in CaMKIIα (Thr 287 in β, γ and δ isoforms). In the
sustained presence of Ca2+/CaM, intersubunit autophosphorylation in these
threonine residues results in Ca2+/CaM-independent CaMKII activity by
preventing the reassociation of the kinase domain with the autoinhibitory domain
(181). The autophosphorylated CaMKII can then be dephosphorylated by either
protein phosphatase 1 (PP1) or PP2A (184-186) to return to the inactive state. The
molecular switch between the Ca2+-dependent and Ca2+-independent CaMKII
activation is critical for the transformation of a transient Ca2+ stimulus into
sustained physiological or disease-causing activity.
Recent studies have shown that the AngII-mediated pathological
responses in the heart involves a second Ca2+/CaM independent activity of
CaMKII under oxidant conditions. More specifically, studies by Erickson et al.
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have shown that oxidation of a paired methionine residue (M281/282) in the
cardiomyocyte isoform of CaMKII (CaMKIIδ) is a downstream signal for AngII
and ischemic stress response in the heart and inhibition of CaMKII protects the
heart against AngII-mediated apoptosis and other pathological myocardial
responses (181, 187). They demonstrated that exposure of purified CaMKIIδ to
H2O2 after pretreatment with Ca2+/CaM yielded persistent CaMKII activation even
in the presence of EGTA suggesting that Ca2+/CaM binding is required for the
initial exposure of the key segment of CaMKII for oxidation as seen with
autophosphorylation and that oxidation is able to maintain sustained CaMKII
activity even without Ca2+/CaM binding. Mutation of M281/282 to valine
completely abolished the H2O2 dependent activation of CaMKIIδ. Since, the
paired met residue is conserved in all three isoforms of CaMKII except CaMKIIα
(188) (CaMKIIα has a cysteine residue for the first methionine of the pair in

position 280), they also generated a M281C mutant of CaMKIIδ and also purified
CaMKIIα. Both purified CaMKIIα and M281C mutant CaMKIIδ were activated by
H2O2 indicating the importance of cysteine in ROS-dependent CaMKII activation.
In addition, heart sections of mice treated with AngII showed increased CaMKII
oxidation whereas mice lacking a critical subunit of NADPH oxidase (p47-/-) did
not show the AngII-mediated increase in CaMKII oxidation (181, 187).
Interestingly, mice knockout for Msr A (MsrA-/-) had increased CaMKII oxidation
and apoptosis with AngII and ischemia along with increased mortality, greater left
ventricular dilation, and reduced in vivo mechanical function after myocardial
infarction (181, 187). More recently, a NO-mediated S-nitrosylation of CaMKIIα
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has been implicated in excitotoxic neuronal cell death (189). The results from that
study show that specific S-nitrosylation of C280/289 generated autonomous
activation of CaMKII independent of Ca2+/CaM binding and mutation of either site
protected from NO-induced neuronal cell death. The redox sensitivity of CaMKII
has also been illustrated in studies where large increases in cytosolic Ca2+
causes mitochondrial O2- generation and upregulation of CaMKII in hippocampal
neurons (190). Activation of CaMKII by this mitochondrial-induced O2- is also
mediated atleast in part by oxidative suppression of protein phosphatases that
dephosphorylate CaMKII. Studies by Yin et al. have also showed that in CATH.a
neurons AngII increases CaMKII phosphorylation, causing CaMKII activation,
with a significant increase observed after 5 minutes of AngII stimulation (83).
However, neurons, which were transduced with AdMnSOD (adenovirus
overexpressing manganese superoxide dismutase) had reduced CaMKII
phosphorylation, indicating that superoxide is involved in mediating AngIIinduced CaMKII activation in central neurons. These studies therefore illustrate
the importance of redox regulation of CaMKII in physiological and pathological
responses.
Specific Aims and Hypotheses
Based on the detailed discussion of the background, the following specific aims
and hypotheses were developed to (1) determine the chronic stability of
exogenous AngII in neuronal cell culture media and (2) examine the redoxsensitivity of neuronal CaMKII (CaMKIIα) in the regulation of neuronal ion

35

channels and increased blood pressure in AngII-dependent neurogenic
hypertension.
The overall hypothesis is that mutation of specific redox-sensitive cysteine
and methionine residues in CaMKIIα will prevent the AngII-mediated inhibition of
neuronal K+ current and also the hypertensive response induced by central or
subcutaneous infusion of AngII. Additionally, a single exogenous administration
of AngII is rapidly metabolized in neuronal cell culture media and in order to
mimic chronic elevated levels of AngII in certain disease models repeated AngII
administration in media is needed. The experiments proposed herein provide
new information on how CaMKIIα can be modified by ROS and exaggerate the
AngII signaling in neurons. More specifically, the results of the study provide
important new insight on the specific residues of CaMKIIα that can be oxidatively
modified and can thus be utilized for the treatment of neuro-cardiovascular
pathologies such as hypertension.

Specific Aim 1: Determine the stability of exogenous AngII in neuronal
culture media.
This aim tests the hypothesis that AngII is rapidly metabolized in neuronal cell
culture media following exogenous AngII stimulation. The levels of AngII and its
metabolites, Ang III, Ang IV and Ang-(1-7), were measured in the media from
cultured CATH.a neurons by liquid chromatography-tandem mass spectrometry.
A single administration of AngII (100 nM) was used to treat CATH.a neurons and
media was collected after 15 minutes – 24 hours to measure AngII and its
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metabolites. AngII levels were also measured after repeated administration of
fresh exogenous AngII every 3 hours for up to 24 hours.
Specific Aim 2: Determine the functional relevance of overexpressing wildtype CaMKIIα in the regulation of AngII-modulated neuronal K+ channel and
the AngII-induced hypertensive response.
This specific aim tests the hypothesis that adenovirus-mediated overexpression
of wt-CaMKIIα (wt-AdCaMKIIα) in CATH.a neurons potentiates the AngIImediated inhibition of K+ current. In addition, we hypothesize that wt-CaMKIIα
overexpression in the brain exaggerates the AngII-induced increase in blood
pressure in mice. A series of in vivo and in vitro experiments were performed to
test the hypothesis. Molecular biology techniques, including polymerase chain
reaction (PCR) and cloning was utilized to generate the major neuronal isoform
of CaMKII (CaMKIIα) adenovirus. The overexpression of wt-CaMKIIα in CATH.a
neurons was assessed by measuring the mRNA and protein expression using
real time PCR and Western blot analysis respectively. Whole-cell patch clamp
technique was utilized to measure changes in baseline K + channel current and
following AngII stimulation in non-infected, control adenoviral, AdEmpty and wtAdCaMKIIα transduced CATH.a neurons. Furthermore, wt-AdCaMKIIα and
adenovirus overexpressing green fluorescent protein (AdGFP) was injected
intracerebroventricularly (ICV) in mice by ICV cannulas and blood pressure and
heart rate responses were measured following either central acute or chronic
subcutaneous AngII infusion. Blood pressure and heart rate responses were
measured using radiotelemetry.
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Specific Aim 3: Determine the functional relevance of oxidative posttranslational modifications of CaMKIIα in regulating neuronal ion channel
current and in mediating AngII hypertension in mice.
Based on the previous studies discussed, both cysteine and methionine residues
present in the autoregulatory domain of CaMKII has been shown to be
oxidatively modified. This aim will therefore test the hypothesis that mutation of
specific redox-sensitive cysteine and methionine residues in CaMKIIα will
attenuate the AngII-mediated inhibition of neuronal K+ current and also the AngIIinduced rise in blood pressure. A mutant CaMKIIα adenovirus (mut-AdCaMKIIα)
was generated with C280A and M281V substitutions and was transduced in
CATH.a neurons to record K+ current at baseline and after 5 minutes of AngII
superfusion. To investigate the effect of mut-CaMKIIα in the brain on the AngIImediated hypertensive response, mice were injected with ICV mut-CaMKIIα
adenovirus and blood pressure and heart rate responses were recorded after
subcutaneous AngII infusion for 3 weeks.
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Figure 1.5. Schematic representation of overall hypothesis. AngII increases
superoxide which in turn leads to enhanced CaMKII oxidation and activation.
Activated CaMKII subsequently decreases neuronal potassium current and
increases neuronal firing frequency. Activation of central neurons leads to an
increased sympathetic nerve activity and an increase in mean arterial pressure
(hypertension).
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Chapter II: Exogenous Angiotensin II is Rapidly Metabolized in
Catecholaminergic Neuronal Cell Culture Media

Introduction

Activation of the renin-angiotensin system along with increased levels of AngII in
the brain has been associated with the development and maintenance of various
forms of experimental and genetic models of hypertension (87, 88, 191, 192). In
the brain, AngII can act on specific nuclei that are important in autonomic control
of cardiovascular function. These brain regions include the subfornical organ
(SFO), paraventricular nucleus (PVN), rostral ventrolateral medulla (RVLM) and
nucleus tractus solitaries (NTS). AngII has been shown to increase neuronal
firing in these brain areas, thus leading to the deleterious sympathoexcitation
commonly associated with neuro-cardiovascular diseases (193-196). In central
neurons, AngII mediates most of its actions by acting primarily on its type 1
receptor (AT1R). For example, AngII stimulation of the AT1R in the above
mentioned cardiovascular control brain regions and others contributes to
vasopressin secretion, thirst and salt appetite, and baroreflex modulation (197199). In addition, AngII can also activate its type 2 receptor (AT 2R) on central
neurons, which often results in opposing responses compared to AT 1R activation,
reflecting the different physiological and pathophysiological roles of AngII
mediated via these receptors (13).
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Considering the importance of AngII intra-neuronal signaling in the
pathogenesis of neuro-cardiovascular diseases including hypertension and heart
failure, numerous studies have been devoted to better understand the precise
signaling pathways involved in an attempt to identify new therapeutic targets for
these diseases. However, there are significant technical challenges in studying
AngII-induced intra-neuronal signaling in vivo in animal models of hypertension
and heart failure such as: 1) limited number of neurons within a specific
cardiovascular control brain region of interest to perform a particular assay; 2)
separating intra-neuronal signaling events from other pathways activated in
neighboring cells including glia and endothelial cells; and 3) separating the
signaling mechanisms of other peptides and hormones associated with these
diseases from those directly induced by AngII. To circumvent these challenges,
neuronal cell culture models have been frequently utilized to examine the specific
intra-neuronal signaling pathways induced by AngII. Such studies have clearly
identified important roles for calcium, reactive oxygen species, kinases, and
transcription factors in the AngII intra-neuronal signaling pathway (80, 84, 86,
90).
Nevertheless, there are also limitations in using neuronal cell culture
models to recapitulate the AngII intra-neuronal signaling events occurring in vivo
such as: 1) neuronal cells are often immortalized and/or isolated from a tumor; 2)
cells are usually cultured in a hyperoxic environment (i.e. 21% oxygen) as
compared to their in vivo environment (1-4% oxygen); and 3) the lack of
neighboring glia and endothelial cells may alter a particular response in the
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cultured neurons that would normally occur in vivo. A fourth limitation in using
neuronal cell culture models as it specifically relates to understanding AngII intraneuronal signaling is the lack of evidence indicating the stability of exogenous
AngII in neuronal cell culture media. Many studies have examined intra-neuronal
responses, such as changes in mRNA levels and protein expression, 1-48 hours
after a single administration of exogenous AngII into the neuronal cell culture
media (200-202). Data from these studies are often interpreted to indicate that the
observed changes are also occurring in neurons of various hypertensive and
heart failure models in which circulating and/or brain levels of AngII are
chronically elevated(203, 204). However, it remains unclear if a single treatment
of exogenous AngII given to neurons in culture results in a chronic elevation of
AngII levels in the media.
In the current study, we tested the hypothesis that exogenous AngII is
rapidly metabolized in neuronal cell culture medium and thus fails to remain
chronically elevated following a single exogenous administration. We utilized a
mouse catecholaminergic neuronal cell line, CATH.a neurons, which express
both AT1R and AT2R. CATH.a neurons have commonly been used by our group
and others to study AngII intra-neuronal signaling pathways (80, 85, 115).
Previous studies have shown that deletion of the AT 1R from catecholaminergic
neurons delays the onset of AngII-dependent hypertension and also reduces the
maximal blood pressure response (205). In addition, catecholaminergic neurons,
such as C1 neurons in the RVLM, play an important role in AngII-induced
hypertension and blocking the AT1R specifically in these neurons can attenuate
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the AngII-mediated rise in blood pressure (206). Using liquid chromatographytandem mass spectrometry, we measured levels of AngII and its metabolites, Ang
III, Ang IV, and Ang-1-7, in CATH.a neuronal cell culture media after
administration of exogenous AngII. Herein, we report that exogenous AngII is
rapidly metabolized in CATH.a neuron media with levels returning to near
baseline after 3 hours of administration. Further, AngII levels in CATH.a neuron
media can be significantly and chronically elevated for at least 24 hours with the
addition of fresh exogenous AngII every 3 hours.

Experimental Methods
Neuronal cell culture
Mouse catecholaminergic CATH.a neurons (American Type Culture Collection
(ATCC), Manassas, VA) were cultured in RPMI 1640 medium (Gibco/Invitrogen,
Grand Island, NY) supplemented with 8% normal horse serum (NHS) (ATCC),
4% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and 1% penicillinstreptomycin (Gibco) at 37 ºC with 5% carbon dioxide (CO2) as recommended by
ATCC. CATH.a neurons were differentiated for 6 - 8 days before experimentation
by adding N6,2′-O-dibutyryladenosine 3′,5′ - cyclic monophosphate sodium salt
(dbcAMP, 1 mM, Sigma-Aldrich, St. Louis, MO) to the culture medium as
previously described (207). Neurons were serum starved for 18-24 hours before
treatment or experimentation. CATH.a neurons are derived from tyrosine
hydroxylase (TH)-positive tumors in the locus ceruleus of transgenic mice
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carrying the SV40 T-antigen oncogene. The CATH.a neuronal culture expresses
tyrosine hydroxylase and dopamine β hydroxylase enzymes thereby producing
norepinephrine and dopamine respectively. It should be noted that CATH.a
neurons express both AT1 and AngII type 2 receptor (AT2R) and have been
widely used by various groups to study AngII intra-neuronal signaling
mechanisms (196, 207, 208).
Liquid chromatography – tandem mass spectrometry (LC-MS/MS)

CATH.a neuronal culture medium was collected after incubation (15 minutes – 24
hours) with AngII (100 nM). 13C- and 15N-labeled (Leu, + 7 amu) AngII (H-AngII,
Anaspec, Fremont, CA) was added to the media samples at a concentration of
18.2 nM. Proteins were precipitated by addition of 6 volumes of cold neat
acetone, typically 50 µl of sample and 300 µl of acetone and stored at -35 ºC for
1 hour. Then, the samples were centrifuged at 4 ºC for 15 minutes at 15,000 x
g. Thereafter, the supernatants were removed and the acetone/water was
removed by SpeedVac concentration for 2 - 3 hours at room temperature. The
pellet was re-dissolved into 50 µl of 0.1% formic acid, vortexed, and
centrifuged. The samples were loaded onto V-shaped polyethylene vials (Agilent,
Santa Clara, CA) that were previously soaked with 0.1% w/v BSA and dried. The
LC-MS/MS method was developed and used for the samples using an Agilent
LC1200 HPLC system (Agilent, Santa Clara, CA) connected to an ABSciex
QTrap4000 (ABSciex, Framingham, MA) operating in multiple reaction monitoring
(MRM) mode with the electrospray operating in positive mode. Other ion-source
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conditions were Temperature, 500 oC, ionization potential, 5500 V, GS1= 50,
GS2= 25, curtain gas= 30. The transitions monitored and ionization parameters
are shown in Table I. Transitions numbered 1,3,5,8 and 9 were used for
quantitation while the remaining ones were used for confirmation of peak
assignment. Column chromatography was performed via a 2.1 x 50 mm Kinetex
C-18 300 Å (Phenomenex, Torrance, CA) at a flow rate of 250 µl/min with a
mobile phase gradient from 98% A (0.1% formic acid in LC-water) to 98% B
(0.1% formic acid in acetonitrile) over 20 min, with additional holding at 98% B for
2 mins and re-equilibration at 98% A for 10 min. Transitions were monitored with
an acquisition time of 100 msec/MRM in non-scheduled mode. The data were
analyzed using Analyst Ver 1.4.2. AngII levels were quantified using H-AngII as a
standard. The other angiotensin peptides (Ang III, Ang IV, and Ang-1-7) were
quantified by comparison to an external calibration curve of the unlabeled
commercially available peptides, and H-AngII was used as a surrogate to correct
for concentration loss of the peptides during sample preparation. The recoveries
of the spiked H-AngII were equal to or higher than 80% for the analytical method.
Individual samples were injected in triplicate and the average angiotensin peptide
concentrations and standard error are reported. All reagents used for LC-MS/MS
analysis were of Mass Spectrometry Grade and all unlabeled angiotensin peptide
standards and reagents were purchased from Sigma-Aldrich (St. Louis, MO).
Statistical analysis
All data are expressed as mean ± standard error of the mean (SEM) and were
analyzed by Student’s t-test for two-group comparisons or by ANOVA followed by
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Newman-Keuls correction for multiple comparisons. Statistical analyses were
performed using GraphPad Prism 5.0 statistical and graphical software.
Differences were considered significant at p<0.05.
Results
Utilizing liquid chromatography – tandem mass spectrometry to detect
angiotensin peptides

AngII is generated from angiotensin converting enzyme (ACE) cleaving
angiotensin I, which is produced by renin-induced cleavage of angiotensinogen.
Although AngII is considered to be the primary effector peptide of the reninangiotensin system, AngII can be further metabolized to other angiotensin
peptides which have been shown to contribute to cardiovascular function (39, 207,
209). For example, AngII can be cleaved by angiotensin converting enzyme 2

(ACE2) (210-212) to form Ang-1-7 or by aminopeptidase A to form Ang III, which is
further metabolized by aminopeptidase N to form Ang IV (Figure 2.1). Although
the primary objective of this study was to examine the stability of exogenous
AngII in neuronal cell culture media, it was also important to determine if
exogenous AngII is metabolized to these other angiotensin peptides.
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Figure 2.1. Schematic of the renin-angiotensin system. AngII is generated by
angiotensin converting enzyme (ACE)-induced cleavage of angiotensin I. AngII is
subsequently metabolized to Ang III and Ang-1-7 peptide via aminopeptidase A
and angiotensin converting enzyme 2 (ACE 2), respectively. Ang III is further
metabolized by aminopeptidase N to generate Ang IV.
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As shown in the representative chromatogram (Figure 2.2), we were able
to successfully separate and detect all four angiotensin peptides from a mixture
containing the commercially available peptides ranging in concentration from 1216 nM. AngII is an octapeptide which under the conditions of the chromatography
should accumulate in the +3 charged state due to the positive charges at the
terminal amino group as well as the Arg and His side chains. Upon loss of the Cterminus Phe, rendering Ang-1-7, the peptide is much less hydrophobic and thus
binds less strongly to the C-18 side chains of the HPLC column particles. Since
Phe is more hydrophobic than Asp, removal of Asp instead of Phe from AngII
makes the Ang III peptide less hydrophobic than AngII but more than Ang-1-7.
Therefore, Ang III elutes between Ang-1-7 and AngII (Figure 2.2). The
hexapeptide Ang IV is generated from the removal of the N-terminus positive side
chain Arg from Ang III, while keeping the hydrophobic residues Ile and Phe. As a
result of Ang IV being the most hydrophobic, it has the strongest binding and thus
appears as the last peak in the chromatogram (Figure 2.2). To accurately
quantify the concentration of these peptides in our subsequent studies using
media samples from the CATH.a neuronal culture, we utilized
labeled AngII (H-AngII).

13

C- and 15N-
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Figure 2.2: Angiotensin peptides detected by liquid chromatographytandem mass spectrometry. Representative chromatogram showing the
detection of individual angiotensin peptides (AngII, Ang III, Ang IV, and Ang-1-7)
in a mixture of the commercially available peptides in a concentration ranging
from 12-16 nM. 13C- and 15N-labeled AngII (H-AngII) was also added to the
mixture and used to quantify absolute amounts of the angiotensin peptides in the
CATH.a neuronal cell culture media samples analyzed in subsequent
experiments.
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Exogenous AngII is rapidly metabolized in CATH.a neuronal cell culture
media

Levels of AngII, Ang III, Ang IV, and Ang-1-7, were measured in CATH.a neuronal
cell culture media 15 min – 24 hours after a single administration of exogenous
AngII (100 nM) into the media. As expected, AngII was significantly elevated in
the media 15 minutes after administration as compared to media collected
immediately prior to treatment (Figure 2.3A). Levels of AngII rapidly decreased
over time until 3 hours-post administration when levels of AngII in the media were
significantly lower compared to the 15 min time-point and not significantly
different than baseline levels. AngII remained low, that is, it was undetectable 6
and 24 hours after administration. Interestingly, levels of Ang III (Figure 2.3B) and
Ang-1-7 (Figure 2.3D) modestly, but significantly, increased 15-60 minutes after
exogenous AngII administration. In contrast, levels of Ang IV remained
unchanged compared to baseline levels (Figure 2.3C). It should be noted that we
specifically selected the AngII concentration of 100 nM for these studies because
we wanted to replicate, as best we could, the experimental conditions used in
other published studies(80, 83) designed to examine the AngII-induced acute and
chronic responses in cultured neurons. For example, we previously used 100 nM
AngII to study AngII-mediated intra-neuronal signaling in CATH.a neurons and
have shown that at this concentration AngII-induced Nox4-generated
mitochondrial superoxide production contributes to the rapid inhibition of outward
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K+ current (83, 115). Furthermore, Sun et al. have reported that 100 nM AngII
rapidly inhibits the delayed rectifier K+ current and increases neuronal firing rate
in primary neurons isolated from the brain (80, 81). Additional studies examining
more long-term changes (i.e. hours to days) in the expression of various proteins,
including AngII receptors, potassium channels, and transcription factors, also
used 100 nM AngII (85, 86, 201, 213).
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Figure 2.3: Exogenous AngII levels rapidly decrease within 3 hours in
CATH.a neuronal cell culture media. Levels of AngII (A), Ang III (B), Ang IV (C),
and Ang-1-7 (D) in CATH.a neuronal cell culture media following a single
administration of exogenous AngII (100 nM) as measured by liquid
chromatography-tandem mass spectrometry. Absolute concentrations were
calculated against the standard 13C- and 15N-labeled AngII peptide. n = 3
separate experiments performed in triplicate. *p < 0.05 vs. 0min AngII; #p < 0.05
vs. 15 min AngII.
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Exogenous AngII is stable in neuronal cell culture media in the absence of
CATH.a neurons

The rapid decrease in exogenous AngII levels in media collected from CATH.a
neurons may suggest that the peptide is degraded by the media itself. To
examine this possibility, AngII (100 nM) was added to the media in the absence
of CATH.a neurons and samples were collected 15 min – 24 hours later (Figure
2.4). AngII levels remained significantly elevated at all time-points with
concentrations near the starting concentration of 100 nM (Figure 4A). In contrast,
levels of Ang III, Ang IV, and Ang-1-7 were not significantly different than baseline
levels (Figure 2.4B-D).
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Figure 2.4: AngII is stable in neuronal cell culture media in the absence of
CATH.a neurons. Levels of AngII (A), Ang III (B), Ang IV (C) and Ang-1-7 (D) in
cell culture media without CATH.a neurons following a single administration of
exogenous AngII (100 nM) as detected by liquid chromatography and tandem
mass spectrometry. Absolute concentrations were calculated against the
standard 13C- and 15N-labeled AngII peptide. n = 3 separate experiments
performed in triplicate. *p < 0.05 vs. 0 min.
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Replenishing CATH.a neuronal cell culture media every 3 hours with fresh
exogenous AngII results in chronic elevated levels

Finally, to determine if levels of AngII could be chronically elevated in CATH.a
neuronal cell culture media, we administered fresh exogenous AngII (100 nM)
every 3 hours and measured AngII for up to 24 hours. As shown in Figure 2.5,
AngII levels remained similarly and significantly elevated (63-72 nM) at each
time-point compared to baseline levels.
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Figure 2.5: Repeated administration of exogenous AngII every 3 hours
maintains a chronic elevated level of AngII in CATH.a neuronal cell culture
media. Levels of AngII in CATH.a neuronal cell culture media following repeated
administration of exogenous AngII (100 nM) into the media every 3 hours for 6, 9,
12, 15, 21, and 24 hours. Absolute concentrations were calculated against the
standard 13C- and 15N-labeled AngII peptide. n = 3 separate experiments
performed in triplicate. *p < 0.05 vs. 0 min.
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Discussion
The pathogenesis of various cardiovascular disorders, such as hypertension and
chronic heart failure, involves dysregulation of the brain angiotensinergic system
(73, 89, 214). Understanding the precise intra-neuronal signaling mechanism(s)
driving this dysregulation may lead to the identification of new targets for which
novel therapeutics can be developed. As such, numerous studies have focused
on examining the intra-neuronal signaling molecules and proteins mediating the
physiological and pathophysiological responses of AngII (14, 97, 109). Many of
these studies have relied on neuronal cell culture models to demonstrate a role
for signaling intermediates, such as calcium, ROS, kinases, and transcription
factors in mediating the AngII-induced response (80, 84, 86, 90). However,
relating these in vitro observations to in vivo AngII-dependent cardiovascular
diseases, such as hypertension and chronic heart failure, where circulating and
central levels of AngII are chronically elevated (203, 204) is problematic as the
stability of exogenously administered AngII in neuronal cell culture media is
unknown. In the current study, we examined the stability of exogenous AngII in
the culture media of an AngII-sensitive neuronal cell culture model, CATH.a
neurons, that has commonly been utilized to study AngII intra-neuronal signaling
(80, 85, 115). Herein, we report that levels of exogenous AngII are diminished to
near baseline levels within 3 hours of treatment, and that media should be
replenished with fresh AngII every 3 hours to maintain chronically elevated levels
of the peptide in this neuronal cell culture model.
Acute stimulation (i.e. minutes) of cultured neurons with AngII results in a
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rapid increase in intracellular calcium (84), inhibition of outward potassium
current (IKv) (80, 83), and an increase in neuronal firing (81). Chronic stimulation
(i.e. hours to days) of AngII-sensitive cultured neurons leads to alterations in the
expression of angiotensin receptors (200, 202), potassium channel proteins (85),
and transcription factors(201). However, in most, if not all, of these chronic
stimulation studies a single administration of exogenous AngII was given to
neurons in culture. This begs the questions of whether AngII remains stable in
the culture media for hours or days to continuously activate its receptors to
mediate these changes in protein expression or if these changes are a result of
the immediate stimulation of AngII receptors followed by prolonged intra-neuronal
signaling events. The more long term changes might be a result of downstream
intermediate signaling events and not a direct effect of AngII binding to its
receptors on these neurons. With these questions unanswered, it is difficult to
compare results obtained from these types of in vitro studies with data obtained
from in vivo cardiovascular disease models in which AngII receptors are likely
constantly activated due to the chronically elevated levels of AngII. Our new data
presented herein indicates that levels of exogenously administered AngII in
neuronal cell culture media are decreased to near baseline levels within 3 hours;
thus, suggesting that changes in protein expression at later time points are due
to prolonged intra-neuronal signaling events rather than continuous activation of
AngII receptors. In fact, we observed that within 15 minutes of treating cells with
100 nM AngII only 53±4 nM AngII remained in the media, and by 3 hours posttreatment less than 5 nM AngII remained. As we report, some of the exogenous
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AngII is metabolized in the media to Ang III and Ang-1-7, as the concentration of
these two peptides increased 15 minutes after AngII treatment. We speculate
that most of the AngII lost within the first 15 minutes of treatment is bound to the
AngII receptors and internalized via receptor-mediated endocytosis. In support of
this hypothesis, previous studies using aortic smooth muscle cells have
demonstrated that after AngII binds to its receptor the complex is internalized
with a half-time of less than 2 minutes (215). In addition, previous reports indicate
a functional role for internalized AngII after it has bound to the AT1R and the
complex has been endocytose (216). For example, the complete AT1R-induced
activation of mitogen‐activated protein kinase (MAPK) is believed to be
dependent on internalization (217). Furthermore, nuclear membrane-associated
angiotensin receptors have been identified (208, 218) and may be stimulated by
internalized AngII and/or by AngII generated via an intracellular renin-angiotensin
system (67).
After observing the rapid decrease in exogenously administered AngII in
the media of our neuronal cell culture model, we questioned whether this was
cell-mediated or non-specific degradation of AngII in the media. To address this
question, we measured levels of AngII in culture media in the absence of CATH.a
neurons after a single exogenous administration of 100 nM AngII, and found that
AngII is relatively stable in the media. More specifically, the concentration of AngII
at all time-points measured (15 minutes to 24 hours) was approximately 80 nM or
greater. Taken together with our results in the presence of CATH.a neurons,
these data suggest that that rapid loss of exogenous AngII in the media of
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CATH.a neurons is mostly cell-dependent with the AngII being metabolized to
Ang III and Ang-1-7, or binding to its receptors, along with some non-specific
degradation of the peptide. As such, it is likely that the stability of exogenous
AngII in cultured media will be drastically different between various cells types.
That is, the expression levels of aminopeptidase A, which cleaves AngII to Ang
III, ACE2, which cleaves AngII to Ang-1-7, and/or AngII receptors in a particular
cell type will influence the stability of exogenous AngII in the respective media.
Although we did not observe a change in Ang IV in the current study with CATH.a
neurons, it is tempting to speculate that the amount of aminopeptidase N, which
cleaves Ang III to Ang IV, expressed by a particular cell line will also contribute to
the levels of these angiotensin peptides in culture media. Furthermore, it is
possible that the stability of AngII in culture media may be experimentally
manipulated by the exogenous administration of aminopeptidase inhibitors, ACE2
inhibitors, and/or AngII receptor antagonists.
In conclusion, our results demonstrate that a single exogenous
administration of AngII to CATH.a neurons in culture does not result in chronically
elevated levels of AngII in the media. As such, we sought to determine if multiple
and sequential administration would keep AngII levels elevated chronically. Our
data show that giving fresh AngII (100 nM) every 3 hours to cultured CATH.a
neurons does indeed keep levels of AngII in the media significantly elevated for
at least 24 hours. We believe cell culture models with chronically elevated levels
of AngII are the ideal in vitro models that one should utilize to study the precise
AngII-dependent intracellular signaling events that occur in cardiovascular
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diseases associated with systemic and/or local chronically elevated levels of
AngII, including hypertension and chronic heart failure. We posit that keeping
levels of AngII chronically elevated in cell culture models will change the cellular
response induced by AngII compared to the response induced by a single
administration. Alternatively, it is possible that AngII levels may not need to be
chronically elevated in cell culture media to induce long-term effects as the initial
stimulation of AngII receptors may activate intracellular signaling pathways that
lead to chronic changes in the expression of AngII receptors, ion channel
proteins, and transcription factors. To address these hypotheses, our laboratory
is currently investigating changes in AngII-dependent intracellular signaling
events in CATH.a neurons exposed to single versus repeated administration of
AngII. More specifically, we are examining changes in AngII receptor expression,
levels of ROS and antioxidants, intracellular calcium concentration, activation of
transcription factors, and expression of ion channels. Importantly, we are
comparing any changes in response to single or repeated administration of AngII
to those that we observe in cardiovascular control brain nuclei (e.g. SFO, PVN,
RVLM) collected from animal models in which AngII is known to be chronically
elevated in the brain, including hypertensive and chronic heart failure models.
We believe these, and other, future studies will provide further insight into the
importance of establishing cell culture models with chronically elevated levels of
AngII to improve our understanding of AngII intracellular signaling pathways.
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Chapter III: Overexpression of wild-type calcium/calmodulin-dependent
protein kinase IIα potentiates angiotensin II-mediated signaling in neurons

Introduction
As described in the previous chapter, we have shown that exogenous AngII
added to neuronal cells in culture is metabolized within 3 hours; whereas, at 15
minutes post-treatment levels of AngII remain significantly elevated in the culture
media. In the current chapter, my overall objective was to determine the
contribution of CaMKII in AngII intra-neuronal signaling. Considering the
observations discussed in the previous chapter, I decided to focus on the acute
(i.e. 5-10 minutes) AngII-induced physiological response, which in cultured
neurons is a change in ion channel activity. In fact, AngII has been shown to
regulate neuronal ion channels, including the voltage-gated potassium and
calcium channels (80, 84). However, the signaling mechanism(s) driving this
response has yet to be precisely identified.
Several studies by Sun and colleagues have shown that AngII can
regulate neuronal K+ current (IKV) thereby increasing neuronal firing rate and
causing neuronal activation (80, 81). More specifically, they showed that AngII
inhibits IKV, particularly the delayed rectifier K+ current and this results in an
increased frequency of neuronal firing both in primary neurons isolated from rat
hypothalamus and brain stem, and in a mouse catecholaminergic neuronal cell
line (CATH.a neurons)(80, 81). Additionally, they showed that the AngII-induced
increase in neuronal firing rate was significantly attenuated in the presence of the
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AngII type 1 receptor (AT1R) antagonist losartan (79). Interestingly, these studies
also demonstrated that the AngII-mediated reduction in IKV and increased
neuronal firing rate involves signaling intermediates, such as phospholipase C
(PLC), protein kinase C (PKC), and calcium/calmodulin-dependent protein kinase
II (CaMKII) (80, 81, 219). These studies elucidated that inhibition of PLC, PKC or
CaMKII using U73122, calphostin C or KN-93, respectively, attenuates AngIImediated reduction of IKV and increased neuronal firing suggesting a critical role
for these signaling proteins in AngII-induced neuronal responses. Although these
data suggest a role for CaMKII in AngII signaling in central neurons, the nonspecificity of the CaMKII inhibitor, KN-93, used in these previous studies brings
into question the precise CaMKII isoform involved. As such, we set out to
specifically investigate the contribution of the predominant neuronal isoform of
CaMKII (CaMKIIα) in mediating the AngII-induced regulation of neuronal ion
channels.
Calcium/calmodulin-dependent protein kinase II (CaMKII) is a
multifunctional enzyme which couples increases in intracellular Ca2+ to regulation
of ion channels. Under resting conditions CaMKII remains inactive, but upon
binding with Ca2+/CaM the autoinhibitory domain of CaMKII is relieved from the
kinase domain and undergoes inter-subunit autophosphorylation of a threonine
residue (T286 in neuronal CaMKIIα isoform). Autophosphorylation in the
regulatory domain causes CaMKII activation enabling it to phosphorylate several
target proteins. Several protein phosphatases, like protein phosphatase 2A
(PP2A) and protein phosphatase 1 (PP1) can then dephosphorylate CaMKII
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leading to its inactive resting state (184-186). The switch between Ca2+/CaMdependent and Ca2+/CaM-independent sustained CaMKII activation is therefore
important in determining the role of CaMKII in physiological and pathological
conditions. Interestingly, recent studies have shown that the AngII-mediated
pathological responses in the heart involves a second Ca2+/CaM independent
activity of CaMKII under elevated ROS conditions. These studies have identified
the CaMKIIδ isoform, which is primarily expressed in cardiomyocytes, as a
downstream target of AngII in case of myocardial infarction and ischemic stress
responses during heart diseases (181, 187, 220). Elevated levels of ROS in
presence of AngII can cause oxidation of a paired methionine residue
(M281/282) in CaMKIIδ, which thereby leads to sustained CaMKIIδ activation
independent of Ca2+/CaM and mediates AngII-stimulated apoptosis in the heart.
Additionally, the study also found that substituting the first methionine (M281) of
CaMKIIδ with a cysteine residue, which is similar to the CaMKIIα isoform, also
sustains CaMKIIδ activation under oxidant conditions. These data provide insight
into the redox sensitivity of CaMKIIα which has a cysteine/methionine
(C280/M281) instead of the paired methionine residues.
Studies in our lab have previously shown that in CATH.a neurons AngII
rapidly activates CaMKII by increasing CaMKII phosphorylation with a significant
increase observed after 5 minutes of AngII stimulation (83). However, in that
study, neurons which were transduced with AdMnSOD (adenovirus
overexpressing manganese superoxide dismutase) had reduced CaMKII
phosphorylation, indicating the involvement of ROS in mediating AngII-induced
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CaMKII phosphorylation. Additionally, scavenging superoxide in CATH.a neurons
also attenuated the AngII-mediated reduction in IKV. In an attempt to identify
specific voltage-gated K+ channels involved in AngII-mediated increased
neuronal firing, Gao et al., have showed that expression of Kv4.3 is
downregulated in presence of AngII stimulation in CATH.a neurons (85).However,
the precise mechanism(s) by which AngII regulates CaMKIIα thereby modulating
neuronal ion channels is not fully understood.
Furthermore, as discussed in Chapter I, AngII in the brain acts on specific
nuclei that are important in autonomic control of cardiovascular function,
including the paraventricular nucleus (PVN), rostral ventrolateral medulla
(RVLM), and nucleus tractus solitarius (NTS) (193, 195, 196). AngII can also
activate neurons of circumventricular organs, such as the subfornical organ
(SFO) and lead to sympathoexcitation, which contributes to hypertensive
symptoms, such as increased vasoconstriction, enhanced salt and water
reabsorption, increased heart rate, and activation of T-lymphocytes and
inflammatory cytokines (194, 197-199). Past studies have also demonstrated that
scavenging superoxide with adenoviral-mediated overexpression of copper-zinc
superoxide dismutase (AdCuZnSOD) in the SFO attenuates blood pressure in an
AngII-infused hypertensive animal model (90). However, the role of downstream
effector molecules, such as CaMKIIα in the brain in mediating the AngII-induced
hypertensive response in animal model is unclear.
In the present study we tested the hypothesis that adenovirus-mediated
overexpression of the wild-type predominant neuronal isoform of CaMKII (wt-
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AdCaMKIIα) exacerbates the AngII-mediated inhibition of neuronal K+ current
and potentiates the AngII-induced hypertensive response in mice. We show that
wt-CaMKIIα overexpression indeed intensifies the reduction of IKV in AngIIstimulated CATH.a neurons and also enhances the AngII-induced pressor
response in mice. Overall, this study implicates CaMKIIα as a key mechanistic
player in AngII-signaling in central neurons.
Experimental Methods

CATH.a neuronal cell culture
For detailed descriptions of mouse CATH.a neuronal cell culture and
differentiation, see experimental methods in Chapter II. During adenovirus
transduction cells were treated with serum free media with dbcAMP for 18-24
hours following which virus was removed and media replaced with serum full
media with fresh dbcAMP.
Adenoviral vector construction
Replication-deficient recombinant adenovirus (Ad5-CMV) encoding mouse wildtype calcium/calmodulin-dependent protein kinase IIα (wt-AdCaMKIIα) was
generated. CaMKIIα plasmid (Origene) was amplified by conventional
Polymerase Chain Reaction (PCR) using the HotStart PCR Master Mix (Qiagen,
Venlo, Limburg) and the following forward and reverse primers: forward 5’- GAA
TTC ATG GCT ACC ATC ACC TGC ACC C – 3’; reverse 5’ – GGA TCC TCA ATG
CGG CAG GAC GGA - 3’. The PCR product was then run on a 1% agarose gel,
followed by gel extraction utilizing QIA quick gel-extraction kit (Qiagen). A pJet1.2
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PCR clone jet kit (Thermo Scientific) was used to clone CaMKIIα insert in various
vector to insert ratios to determine the optimum ratio for cloning. It was then
transformed into DH5 alpha bacteria and grown overnight onto ampicillin treated
plates at 37oc in a bacterial incubator. Bacterial colonies were picked and grown
in luria broth (LB) media overnight by shaking. PureLink Quick Plasmid DNA
Miniprep Kits (Invitrogen, Grand Island, NY) were used to isolate CaMKIIα
plasmid DNA as per manufacturer’s instructions. Following quantification of the
DNA using a Nanodrop 2000 spectrophotometer (Thermo Scientific, Waltham,
MA) 1µg DNA was digested with EcoR1 and BaMH1 (New England Biolabs,
Ipswich, MA) restriction enzymes and then run on a 1% agarose gel to confirm
the presence of the correct insert. The plasmid samples were then sent off to the
UNMC Gene Sequencing Core. Once the wt-CaMKIIα sequence was confirmed it
was then cloned into an expression plasmid, transformed into DH5 alpha
bacteria, DNA isolated, digested using restriction enzymes and again sent to the
UNMC Gene sequencing core to confirm the presence of correct wt-CaMKIIα
sequence in the expression plasmid. Adenoviral vectors were then constructed,
purified and provided by the University of Iowa Gene Vector Core as previously
described (83, 221).
RNA extraction, cDNA and quantitative real-time RT-PCR
To confirm the overexpression of wt-CaMKIIα at the transcriptional level and to
evaluate the effect of wt-CaMKIIα overexpression on other CaMKII isoforms, total
RNA was extracted from differentiated CATH.a neurons using the Trizol method
(Life technologies, Carlsbad, CA) according to the manufacturer’s protocol. RNA
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concentration was determined spectrophotometrically by using a Nanodrop 2000
Spectrophotometer (Thermo Scientific). 1 µg of each sample RNA was reverse
transcribed and cDNA was generated by Taqman reverse transcription kit
(Applied Biosystems, Foster City, CA). SYBR green (Applied Biosystems)
quantitative real-time PCR was performed with generated cDNA with primers
specific to the coding sequence of CaMKIIα, CaMKIIβ, CaMKIIδ, CaMKIIγ.
Additional primers specific to voltage-dependent K+ channels such as KV2.1, KV2.2,
KV4.2 and KV4.3 were also used. Primer sequences were as follows: CaMKIIα
forward, 5’- TGA CAG CCT TTG AAC CAG AG - 3’; CaMKIIα reverse, 5’- CAA
AAT AGA ATC GAT GAA AGT CCA - 3’; CaMKIIβ forward, 5’- GGA CAT CTG
GGC ATG TGG - 3’; CaMKIIβ reverse, 5’- CAC TCA GGG GAT GGG AAA T -3';
CaMKIIδ forward, 5’- TCA ACC CTG CCA AAC GTA TC - 3’; CaMKIIδ reverse, 5’
– GAG GCA ACA GTA GAG CGT TGA - 3’; CaMKIIγ forward, 5’ – GCT CAA TGT
CCA CTA TCA CTG C - 3’; CaMKIIγ reverse, 5’ – TCA CTC AGG CCC TCC AGA
– 3’; Kv2.1 forward, 5’ – GGA GAA GCC CAA CTC ATC G - 3’; Kv2.1 reverse, 5’
– TGT TGA GTG ACA GGG CAA TG – 3’; Kv2.2 forward, 5’ – CCG GAG AAA
CGG AAG AAA C - 3’; Kv2.2 reverse, 5’ – ATA GAC ACG ATG GCC AGG AT – 3’;
Kv4.2 forward, 5’ – GCT TTG AGA CAC AGC ACC AC - 3’; Kv4.2 reverse, 5’ –
TGT TCA TCG ACA AAC TCA TGG – 3’; Kv4.3 forward, 5’ – TGC CAC TGT GAT
GTT TTA TGC - 3’; Kv4.3 reverse, 5’ – TCT TAG GCA CCA TGT CTC CA – 3’
The PCR parameters were 95oc for 10 minutes, followed by 40 cycles of 95oc for
15 seconds and 60oc for 1 minute. Thermal dissociation was used to determine
PCR product specificity. Briefly, a threshold in the linear range of PCR
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amplification was selected and the cycle threshold (Ct) was determined. Levels
of transcripts were then normalized to the 18S rRNA loading control and
compared relative to the control sample using the ΔΔ Ct method.
Western blot analysis
To determine the optimal overexpression of CaMKIIα, CATH.a neurons were
transduced with wt-AdCaMKIIα on day 3 of differentiation and Western blot
analysis was performed to confirm CaMKIIα overexpression. Protein expression
of total CaMKIIα, phosphorylated CaMKIIα (P-CaMKIIα) and actin was
determined using standard Western blot analysis in whole cell lysates prepared
from differentiated CATH.a neurons either non-transduced or transduced with
control adenoviral vector, AdEmpty (10, 25 and 50 multiplicity of infection (MOI) ,
or wt-AdCaMKIIα (10, 25 and 50 MOI). Briefly, cells were harvested in phosphate
buffer saline (PBS) containing protease inhibitor cocktail (Sigma-Aldrich) and
phosphatase inhibitor (Thermo Scientific) and then sonicated. Cell lysates (25-30
µg of protein per lane) were loaded onto 12.5% Bis-Tris gels, separated by SDSPAGE and transferred to a nitrocellulose membrane. Membranes were incubated
at 4 ºC overnight with primary antibodies directed against CaMKIIα (1:1000
dilution, abcam, Cambridge, UK) P-CaMKIIα (1:1000 dilution, abcam) and actin
(1:1000 dilution, Sigma-Aldrich). After incubation with goat anti-rabbit horseradish
peroxidase-conjugated secondary antibody (1:5000 dilution, Thermo Scientific)
for two hours at room temperature, bands were visualized using the Pierce
enhanced chemiluminescence detection system (Thermo Scientific, Rockford,
IL). Densitometric analysis of band density was determined using National
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Institutes of Health (NIH) ImageJ analysis software. Values were normalized to
actin to correct for any variations in protein loading.
Electrophysiological record of voltage-gated K+ currents
Differentiated CATH.a neurons either non-transduced or transduced with
AdEmpty (25MOI), or wt-AdCaMKIIα (25MOI) were used to measure K+ currents
(IKV). IKV was recorded by the whole-cell configuration of the patch-clamp
technique using an Axopatch 200-B patch-clamp amplifier (Axon Instruments,
Inc, Union City, CA). Briefly, in the voltage-clamp experiments, resistance of the
patch pipette was 4-6 MΩ when filled with the following solution (in mM): 130
KCl, 2 MgCl2, 0.25 CaCl2, 5 EGTA, 1 Mg-ATP, 0.1 Tris-GTP, 10 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), and 8 glucose, pH 7.2.
The extracellular solution consisted of (in mM): 137 NaCl, 5.4 KCl, 1.35 CaCl2, 2
MgCl2, 0.3 NaH2PO4, 10 HEPES, 10 sucrose, pH 7.4. To selectively record IKV,
Na+ and Ca2+ channels were blocked by 0.5µM tetradotoxin (TTX, Sigma-Aldrich)
and 0.3 mM CdCl2 (Sigma Aldrich), respectively. Current traces were sampled at
10 kHz and filtered at 5 kHz. Holding potential was -80 mV and current-voltage (IV) relationship was elicited by 10 mV step increments to potentials between -80
and +80 mV for 400 ms. The change of IKV with AngII was tested by superfusing
CATH.a neurons with AngII (100 nM) for 5 minutes and repeating the voltage
pulse regimen. To confirm the observed changes with AngII, IKV was recorded
again after 15 minutes of washout. Cells that responded to AngII stimulation and
then recovered with the washout were considered for data analysis. Current
density of IKV was calculated by dividing the respective current by cell membrane
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capacitance (Cm). The Cm of CATH.a neurons utilized in the study ranged from
10-60 pF and was not significantly different between the groups. The pClamp
10.2 program (Axon Instruments) was used for data acquisition and analysis. All
experiments were carried out at room temperature.
In vivo mouse studies
All animal procedures were reviewed and approved by the University of
Nebraska Medical Center Institutional Animal Care and Use Committee, and
were performed in accordance with the Guidelines for the Care and Use of
Experimental Animals of the American Physiological Society and the National
Institutes of Health. Adult C57BL/6 male mice 7-8 weeks of age (20 - 26 g body
weight) were acquired from Harlan laboratories (Indianapolis, IN) for the in vivo
experiments. Mice were individually housed in temperature and humiditycontrolled cages at the University of Nebraska Medical Center animal facilities
with a 12 hour light-dark cycle. Mice were provided standard chow and water ad
libitum. At the end of each experiment mice were euthanized with intraperitoneal
injection of pentobarbital (150 mg/kg).
Implantation of radiotelemeters in mice
For blood pressure recordings anesthetized mice were surgically instrumented
with left carotid radiotelemeters (TA11PA-C10 catheter, Data Sciences
International, St. Paul, MN). Mice were anesthetized with 0.5-2.0% isofluorane
and a ventral midline skin incision was made from the jaw to the sternum to
carefully isolate the common carotid artery. A tiny incision was made in the
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carotid artery and the telemeter catheter was advanced so that the tip was
positioned inside the thoracic aorta. The transmitter of the radiotelemeter was
placed in a subcutaneous pouch in the right abdominal flank of each mouse. The
neck incision was then closed with an interrupted suture using a prolene
monofilament suture material (Ethicon, Inc). Topical bupivacaine (AAP
Pharmaceuticals, LLC, India) was applied on the surgical site. For real-time
measure of cardiovascular parameters, such as mean arterial pressure, systolic
pressure, diastolic pressure, heart rate and pulse pressure, mice were placed on
individual telemeter receivers after magnetically activating the radiotelemeters.
Data were viewed using Dataquest Advanced Research Technology version 4.1
Data Acquisition and Analysis software and analyzed with Microsoft Excel.

Figure 3.1: Placement of radiotelemeter catheter in the intracarotid artery.
Image from: www.ddah.org.uk/phenotyping-telemetry.htm
Intracerebroventricular (ICV) cannula implantation in mice
Anesthetized mice were strategically placed on a stereotaxic apparatus (World
Precision Instruments) with the help of ear bars. A ventral midline incision was
made on the scalp and the head was leveled so as the lambda and bregma was
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in the same horizontal plane. An anchoring screw was inserted into the right
frontal bone slightly anterior to the coronal suture. The cannula (25 gauge,
Plastic One, Roanoke, Virginia) was then placed 0.3 mm posterior and 1 mm
lateral to the bregma and a hole was dilled following which the cannula was
inserted into the hole 3.3 mm below the bregma and affixed to the skull with
acrylic dental cement (Stoelting, Wood Dale, Illinois). A stylus, specifically fitted to
the length of the cannula, was inserted into the cannula to maintain an
unobstructed opening into the ICV system. Note that mice which received both
radiotelemeter implantation and ICV cannula had their cannulas placed on the
same day immediately following radiotelemetry surgery.

Intracerebroventricular administration of AngII and AdGFP and wtAdCaMKIIα adenoviruses

All ICV injections were made through a 33-gauge stainless steel injector
connected to a Hamilton microsyringe via PE-10 tubing. For the acute studies,
following 1 week of recovery from ICV cannula and radiotelemetry implantation
surgery, the mice received a single acute ICV AngII (350 ng) injection. Blood
pressure and heart rate responses were recorded in conscious freely, moving
mice for 20 minutes after injection. 3 days of acute AngII response was recorded
prior to injecting adenoviruses. Mice were injected with either ICV AdGFP or wtAdCaMKIIα (5x107 plaque forming units). Following adenovirus injection,
baseline blood pressure was recorded for 3 days after which acute physiological
experiments were performed again in presence of ICV AngII. For
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immunohistochemistry studies, 7 days after adenovirus injection, mice were
euthanized with intraperitoneal injection of fatal plus (40 mg/kg, Henry-Schrein,
Inc., Melville, NY). Brains were removed and fixed in 4% paraformaldehyde in 0.1
M phosphate buffer (PB) and then stored in 30% sucrose in PB overnight prior to
sectioning. For the chronic AngII-induced hypertension studies ICV cannulainstrumented mice received either AdGFP or wt-AdCaMKIIα adenovirus (5x107
plaque forming units) 3 days prior to osmotic minipump implantation.

Figure 3.2: Intracerebroventricular cannula implantation for AngII and
adenovirus injection to the subfornical organ.
Modified from: Peterson et al. Hypertension. 2009 (111).
Subcutaneous implantation of osmotic minipumps in mice
For chronic AngII infusion studies mice were implanted 3 days post adenovirus
injection with osmotic minipumps (Alzet, Durect Corporation, Cupertino, CA)
subcutaneously to deliver either Ang II (400 ng·kg-1·min-1) or saline for
approximately 3 weeks. It is to be noted that the dose of AngII was selected
based on previous studies demonstrating that this slow pressor model of AngII

74

hypertension induces a gradual increase in blood pressure that mimics human
essential hypertension (222, 223). The osmotic minipumps were primed at least
for 12 hours in saline at 370c prior to implantation. On the day of surgery, mice
were anesthetized (0.5 – 2.0% isoflurane) and the left flank was shaved. A small
horizontal incision was made in the left flank and a subcutaneous pocket was
created to insert the osmotic minipumps. The incision was closed with an
interrupted suture using a prolene monofilament suture (Ethicon, Inc.). Topical
bupivacaine (AAP Pharmaceuticals) was then applied to the incision site.

75

Figure 3.3: Timeline for acute central AngII-mediated pressor response
prior to and following central administration of wt-CaMKIIα adenovirus.

Figure 3.4: Timeline for chronic subcutaneous AngII-mediated pressor
response following central administration of wt-CaMKIIα adenovirus.
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Immunohistochemistry
To verify the overexpression of CaMKIIα in mouse brain tissues
immunohistochemical staining was performed in brain sections 7 days post ICV
adenovirus injections. 20 µm sections of the mouse brains were prepared using a
cryostat (Leica CM3050S) and immunohistochemistry was carried out. Sections
were first incubated for 1 hour with blocking buffer (10% NHS in 0.1 M PB) and
then incubated at 4 ºC overnight with a rabbit primary antibody against CaMKIIα
(1:200, abcam) and a rabbit P-CaMKIIα (1:200, abcam) prepared in 0.1 M PB
containing 2% NHS and 0.3% Triton X-100. The sections were then washed in
0.1 M PB and incubated with Alexa Fluor 598 secondary antibody (1:200,
Invitrogen) at room temperature for 2 hours. Fluorescent images of the
subfornical organ and ventricles were detected by confocal laser scanning
microscopy (Zeiss LSM 510 Meta Confocal Microscope) at 20X and 40X
magnification.
Statistical Analysis
All data are presented as means ± standard error of the mean (SEM). Data were
analyzed by Student’s t-test for two group comparisons or by ANOVA with
Newman Kewls post-hoc test. P-value less than 0.05 was considered statistically
significant. Statistical analyses were performed using GraphPad Prism 5.0
statistical and graphical software.
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Results
Adenoviral-mediated transduction of wt-CaMKIIα increases total and
phosphorylated CaMKIIα protein in CATH.a neurons
To confirm the adenovirus efficiency and overexpression of CaMKIIα, mouse
CATH.a neurons were either non-transduced or transduced with control
adenovirus, AdEmpty, or wt-AdCaMKIIα at 10, 25 and 50MOI on day 3 of
differentiation. As compared to non-transduced or AdEmpty-transduced neurons,
CATH.a neurons transduced with wt-AdCaMKIIα had a significant increase in
total CaMKIIα protein levels at 25 and 50 MOI as detected by Western blot
analysis (Figure 3.5A). This was accompanied by an increase in phosphorylated
levels of CaMKIIα suggesting an increase in active CaMKIIα in CATH.a neurons
at 25 and 50 MOI (Figure 3.5B). CaMKIIα mRNA overexpression was also
confirmed by real-time quantitative PCR in differentiated CATH.a neurons. While
transduction with wt-AdCaMKIIα resulted in a significant dose-dependent
increase in CaMKIIα mRNA in CATH.a neurons, the other isoforms of CaMKII,
such as CaMKIIβ, CaMKIIδ and CaMKIIγ did not change in between groups
(Figure 3.5C). Kinase activity assay was utilized to measure CaMKII activity in
AdEmpty (25MOI) and wt-AdCaMKIIα (25MOI)-transduced CATH.a neurons.
Neurons with wt-CaMKIIα overexpression had 3-fold higher activity as compared
to AdEmpty-transduced neurons (n = 2).
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Figure 3.5. Transduction of wt-CaMKIIα adenovirus causes significant
upregulation of CaMKIIα expression and activity in CATH.a neurons. (A)
Representative Western blot analysis of CATH.a neuronal cell lysates probed for
primary antibody against total and phosphorylated CaMKIIα; Summary densitometry
data of Western blot analysis showing levels of (B) CaMKIIα and (C) P-CaMKIIα in
non-transduced, AdEmpty (10, 25 and 50 MOI)- and wt-AdCaMKIIα (10, 25 and 50
MOI)-transduced neurons; Real-time RT-PCR data with primers specific for CaMKIIα
(D), CaMKIIβ (E), and CaMKIIδ (F) genes normalized to 18s rRNA and expressed as
fold control; (G) CaMKII activity in AdEmpty (25MOI) and wt-AdCaMKIIα (25MOI)transduced neruons as measured by kinase activity assay and reported as fold
change from control. *P<0.05 vs. non-transduced and AdEmpty.
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Wild-type CaMKIIα overexpression potentiates AngII-mediated inhibition of
K+ channel current in CATH.a neurons
To investigate the effect of wt-CaMKIIα overexpression on the AngII-dependent
changes in electrophysiological properties, voltage-gated K+ channel current (IKV)
was measured in differentiated non-transduced, either AdEmpty or wtAdCaMKIIα-transduced CATH.a neurons. Whole-cell patch-clamp technique was
used to record baseline IKV and IKV after 5 minutes of AngII (100 nM) superfusion.
Compared to baseline, 5 minutes of AngII superfusion inhibited IKV by 20% in
non-transduced and AdEmpty-transduced CATH.a neurons and this effect of
AngII could be restored after AngII washout (Figure 3.6). Interestingly, AngII
superfusion caused a significant reduction in IKV by approximately 37% in wtAdCaMKIIα-transduced CATH.a neurons. It is to be noted that AngII attenuated
both transient K+ current (Ipeak) and the steady-state K+ current (Iss) to a similar
extent in CATH.a neurons as previously described (241). To confirm our finding
that the AngII-induced reduction in IKV was mediated by CaMKII, CATH.a neurons
were pretreated for 30 minutes with the CaMKII inhibitor, KN-93 (10 µM) and
baseline IKV recordings were measured followed by 5 minutes of AngII
superfusion and wash out. The AngII-mediated reduction in IKV was significantly
abolished in presence of KN-93. These data indicate that wt-CaMKIIα
overexpression enhances the AngII-induced inhibition of neuronal K+ channel
current in CATH.a neurons.
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Figure 3.6. Wild-type CaMKIIα overexpression potentiates the AngIImediated inhibition of outward K+ current in CATH.a neurons.
Representative traces of evoked K+ currents in CATH.a neurons superfused with
vehicle or 100 nM AngII (A) and percent inhibition of outward K+ current following
5 minutes of AngII (100 nM) superfusion pretreated for 30 minutes in the absence
or presence of 10 µM KN 93 (B) in non-transduced, AdEmpty (25MOI) or wtAdCaMKIIα (25 MOI)-transduced CATH.a neurons (n = 7 biological replicates for
all experimental groups). *P < 0.05 vs. non-infected. #P < 0.05 vs. no KN 93.
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Wild-type CaMKIIα overexpression upregulates mRNA expression of Kv
channels in CATH.a neurons
To determine the causal relationship between overexpression of wt-CaMKIIα and
significant reduction in K+ current in CATH.a neurons, we sought to detect mRNA
expression of specific voltage-dependent K+ channels which have previously
been shown to be present in important autonomic regions of the brain and also
involved in AngII-mediated signaling in neurons (85, 224). Quantitative real-time
PCR was utilized with specific primers for individual Kv channel transcript to
detect mRNA levels of Kv2.1, Kv2.2, Kv4.2 and Kv4.3. Interestingly, as compared to
AdEmpty-transduced CATH.a neurons, transduction of wt-AdCaMKIIα modestly
increased mRNA expression of the above mentioned KV channels in CATH.a
neurons at baseline (Figure 3.7). These data indicate that overexpression of wtCaMKIIα leads to transcriptional upregulation of these voltage-dependent K+
channels which may act as a compensatory mechanism to counteract the
decrease in channel current.

85

A

B

C

D

Figure 3.7. Overexpression of wt-CaMKIIα modestly increase mRNA
expression of voltage-dependent K+ channels in CATH.a neurons.
Quantitative real-time PCR analysis showing (A) Kv2.1, (B) Kv2.2, (C) Kv4.2 and
(D) Kv4.3 mRNA levels in AdEmpty (25MOI) and wt-AdCaMKIIα (25MOI)
transduced CATH.a neurons. n=3 biological replicates in all experimental groups.
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Overexpression of wt-CaMKIIα potentiates the central acute AngII-induced
increase in mean arterial pressure
Our in vitro studies suggest that overexpressing CaMKIIα in CATH.a neurons
exacerbates the AngII-mediated reduction of neuronal K+ channel current. To
determine the role of CaMKIIα overexpression in the brain on central actions of
AngII in vivo, C57BL/6 male mice underwent radiotelemetry implantation and
intracerebroventricular (ICV) cannula surgeries. Following a week’s recovery,
blood pressure responses to ICV administered AngII (350 ng) were recorded in
conscious mice. As seen in the representative recordings mice receiving acute
ICV AngII had a characteristic significant increase in blood pressure as compared
to their baseline blood pressure (Figure 3.8A). Interestingly, 3 days post
adenovirus injection, the AngII-mediated rise in blood pressure was further
potentiated in ICV AdCaMKIIα-injected (n = 9) mice as compared to AdGFPinjected (n = 9) mice. The peak changes in mean arterial pressure following
acute ICV AngII injections in AdCaMKIIα and AdGFP mice group are summarized
in Figure 3.8B. In addition, the duration of the AngII-induced pressor response
was also longer in CaMKIIα-overexpressed mice as compared to mice receiving
AdGFP (Figure 3.8C). The duration of the AngII-mediated response was
calculated from the start of the peak AngII-induced rise in blood pressure until the
time when blood pressures came back to half the maximal response.
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Figure 3.8. Overexpression of wt-CaMKIIα in the brain potentiates the
pressor response of central acute AngII. (A) Representative mean arterial
pressure tracings and (B) summary data showing AngII-induced acute pressor
response in mice injected with ICV AngII (350 ng) both pre- and 3 days post-ICV
injection of AdGFP or wt-CaMKIIα adenovirus. (C) Duration (in minutes) of the
AngII-mediated rise in blood pressure in AdGFP and wt-AdCaMKIIα injected
mice. *P < 0.05 vs. AdGFP. n = 8-9 mice for each experimental group.
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To confirm efficient adenovirus-mediated overexpression of wt-CaMKIIα in
the subfornical organ (SFO), an important cardiovascular regulatory brain
nucleus, immunohistochemistry was performed on AdGFP and wt-AdCaMKIIαinjected mice brain tissue sections 7 days post ICV adenovirus injections. As
shown in the representative confocal microscopy images, the SFO of wtAdCaMKIIα injected mouse brains possessed higher levels of CaMKIIα
fluorescence in comparison to AdGFP brain sections (Figure 3.9). Together, the
data presented here strongly indicate that CaMKIIα in the brain is an important
player in central AngII-mediated cardiovascular effects.
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Figure 3.9. Adenoviral-mediated overexpression of wt-CaMKIIα in the
subfornical organ (SFO). Representative confocal microscopy images showing
expression of (A) GFP, CaMKIIα and (B) GFP , P-CaMKIIα in SFO of mice 1
week after intracerebroventricular (ICV) injection of AdGFP or wt-AdCaMKIIα.
Coronal brain sections (20 µm) were stained for GFP (green), total and
phosphorylated CaMKIIα (red). Double staining is shown in the merged (yellow)
images. Scale bar = 100 µm
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Adenovirus-mediated wt-CaMKIIα overexpression in the brain sensitizes
mice to an immediate increase in blood pressure following subcutaneous
AngII infusion
We next evaluated the effect of ICV administered wt-CaMKIIα on the slow
pressor AngII-induced hypertensive model. Similar to the acute AngII studies,
mice were implanted with radiotelemeters and ICV cannulas for adenovirus
injections. Following 1 week of recovery from surgery ICV AdGFP and wtAdCaMKIIα adenovirus was injected. Blood pressure and heart rate responses
were recorded in conscious mice after subcutaneous AngII (400 ng/kg/min) or
saline osmotic minipump implantation 3 days post adenovirus injection.
Interestingly, blood pressure was significantly elevated following 2 days of AngII
infusion in wt-AdCaMKIIα-injected mice group and continued to increase
gradually until day 23 when the minipumps emptied and blood pressure came
back to basal levels (Figure 3.10A). In contrast, blood pressure in AdGFPinjected mice increased gradually with AngII infusion with a peak at around day
16 and then came back to baseline levels at day 23-24 when the osmotic
minipumps were empty. It should be noted that the blood pressure response
following subcutaneous AngII infusion in case of AdGFP-injected mice is
characteristic of a slow pressor AngII-induced hypertensive model. Systolic and
diastolic blood pressures followed similar pattern as the mean arterial pressure
(Figure 3.10B and C). Heart rate was not significantly different in between AdGFP
and wt-AdCaMKIIα groups infused with AngII. Blood pressure and heart rate
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responses did not differ in case of saline infused animals. Overall, these studies
indicate that CaMKIIα overexpression in the brain sensitizes mice to an
immediate increase in blood pressure at an initial subpressor dose of
subcutaneous AngII.

93

A

B

94

C

D

95

Figure 3.10. Overexpression of wt-CaMKIIα in the brain sensitizes mice to
an immediate increase in blood pressure following chronic subcutaneous
AngII infusion. Representative line graphs showing (A) mean arterial pressure,
(B) systolic blood pressure, (C) diastolic blood pressure and (D) heart rate
recorded via radiotelemetry in C57BL/6 mice at baseline, following
intracerebroventricular injection of AdGFP or wt-AdCaMKIIα, and after
subcutaneous implantation of osmotic minipumps set to release saline or AngII
(400 ng/kg/min). *P < 0.05 vs. AdGFP mice with AngII infusion. n = 6-9 mice for
each experimental group.
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Discussion
Considering the importance of AngII signaling in central neuronsand its
contribution to neuro-cardiovascular diseases, such as hypertension and heart
failure, it is necessary to investigate the intra-neuronal signaling mechanisms
mediated by AngII and the role of secondary intermediates in AngII-neurogenic
hypertension. In central neurons AngII increases intracellular Ca2+, activates
redox mechanisms including NADPH oxidases, signaling intermediates, and
transcription factors leading to a variety of physiological and pathophysiological
responses (13, 84, 86, 115, 213). However, the underlying mechanism by which
specific redox-sensitive downstream signaling molecules, more specifically
neuronal calcium/calmodulin-dependent protein kinase IIα (CaMKIIα) modulates
AngII-signaling in neurons is unclear. We report here that adenoviral-mediated
overexpression of wt-CaMKIIα in central neurons potentiates the AngII-regulated
intra-neuronal signaling and the AngII-induced hypertensive response. The main
findings from these set of studies can be summarized as follows: (1) wt-CaMKIIα
overexpression in mouse catecholaminergic neurons (CATH.a neurons)
exacerbates the AngII-mediated inhibition of neuronal K+ channel current (Ikv); (2)
intracerebroventricular (ICV) injection of wt-CaMKIIα in the brain potentiates the
central acute AngII-induced pressor response; and (3) ICV injection of wtCaMKIIα sensitizes mice to an immediate increase in blood pressure at an initial
subpressor dose of subcutaneous chronic AngII infusion.
Previous studies have identified protein kinases, such as CaMKII and
protein kinase C (PKC) as signaling intermediates in AngII-stimulated neurons
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(80, 81, 219). For example, two previous studies have shown a clear contribution
of CaMKII and PKC in mediating the AngII-induced inhibition of neuronal ion
channels and subsequent increase in neuronal firing both in primary neuronal
cultures as well as in neuronal cell lines (80, 136). One previous study from our
lab has also demonstrated activation of CaMKII by inducing CaMKII
phosphorylation in AngII-stimulated CATH.a neurons and this CaMKII
phosphorylation can be blocked by overexpressing mitochondrial-targeted
manganese superoxide dismutase (83). These studies therefore suggest CaMKII
as a key player in AngII-mediated signaling in neurons. Additionally, Erickson et
al. have shown that AngII can induce CaMKIIδ oxidation in cardiomyocytes in a
paired methionine residue and sustain CaMKIIδ activity independent of
Ca2+/CaM binding (181). This sustained activity of CaMKIIδ leads to AngIImediated apoptosis in ischemic heart and under myocardial infarction conditions.
Although these studies indicated CaMKII as an important downstream molecule,
in the present study we wanted to specifically investigate the role of major
neuronal isoform of CaMKII (CaMKIIα) in mediating AngII intra-neuronal signaling
and the AngII-induced hypertension.
To determine the role of CaMKIIα in mediating the AngII-induced
reduction in neuronal Ikv, we used adenoviral-mediated overexpression of wtCaMKIIα in CATH.a neurons and measured changes in outward K + current.
Consistent with previous findings, AngII stimulation inhibited Ikv by almost 16%
both in non-transduced as well as in AdEmpty-transduced neurons. Interestingly,
this effect was significantly exaggerated in wt-AdCaMKIIα-transduced neurons. In
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addition to enhancing the AngII effects wt-CaMKIIα overexpression by itself had a
lower baseline Ikv in CATH.a neurons. To correlate changes in baseline
electrophysiological properties with ion channel expression we also investigated
the basal expression levels of different voltage-gated K+ channels that could
potentially play a role in CaMKIIα-mediated Ikv reduction. Previously Gao et al.
have shown that in neurons isolated from the rostral ventrolateral medulla of
chronic heart failure animals as well as in AngII-stimulated CATH.a neurons
expression of Kv4.3, one of the important voltage-gated K+ channels, is
downregulated (85). In the present study we found an upregulation in the basal
gene expression of four of the voltage-gated K+ channels, Kv2.1, Kv2.2, Kv4.2 and
Kv4.3 in CATH.a neurons with wt-CaMKIIα overexpression. We speculate that this
increase in mRNA expression of these channels could be a potential
compensatory mechanism as a result of wt-CaMKIIα overexpression and
subsequent inhibition of Ikv. However, further studies are needed to determine the
protein expression and the cellular localization of these voltage-gated channels in
wt-CaMKIIα-overexpressed and control neurons.
In the central nervous system AngII acts on its type 1 receptor (AT1R) to
promote vasopressin secretion, thirst and salt appetite, sympathetic outflow and
also modulates baroreflex sensitivity (73, 199, 212). Brain AngII is known as a
potent regulator of arterial blood pressure and when administered acutely in an
ICV route it elicits a classic transient systemic and bradycardic response. As
seen in Figure 3.8, acute ICV injection of AngII caused a characteristic rapid and
relatively short-lived increase in mean arterial pressure in AdGFP-treated mice.
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In contrast the AngII-induced increase in blood pressure was significantly
potentiated in mice injected with ICV wt-AdCaMKIIα. We did not observe
changes in baseline blood pressure or heart rate with ICV wt-AdCaMKIIα
overexpression as opposed to our in vitro patch-clamp data. This could be due to
a variety of reasons: firstly, our in vitro studies are carried out in a homogenous
CATH.a neuronal cell population where as in the brain different cell types
including astrocytes, glial cells and endothelial cells have their own signaling
pathways but can also interact with neuronal signaling. Secondly, although we
clearly demonstrate CaMKIIα overexpression in the subfornical organ when given
ICV, we cannot rule out the possibility that the adenovirus is being taken up by
other cardiovascular brain nuclei or even some non-cardiovascular brain regions.
Furthermore, other downstream mechanisms may be involved in vivo to
counteract any mild change in baseline blood pressure or heart rate that may be
occurring with wt-CaMKIIα overexpression.
The slow pressor chronic AngII-induced hypertensive model has been
extensively used by our lab and others to investigate intraneuronal signaling
mechanisms in AngII-mediated neurogenic hypertension (115, 222, 223). We
therefore wanted to evaluate the role of ICV wt-CaMKIIα injection on chronic
subcutaneous AngII infusion and the AngII-induced hypertensive response.
Consistent with the acute AngII data, ICV wt-CaMKIIα did not alter baseline blood
pressure (baseline blood pressure ~ 95 mmHg). Intriguingly, we observed a
significant rise in blood pressure in wt-AdCaMKIIα-injected mice immediately
after the start of AngII infusion as compared to a more gradual rise in AdGFP-
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injected mice and this was maintained up to 2-3 days post minipump
implantation. We speculate that mice receiving wt-CaMKIIα injection in the brain
are being sensitized to an immediate increase in blood pressure at an early
subpressor dose of chronic subcutaneous AngII infusion. Further studies are
needed to determine the mechanism of action by which wt-CaMKIIα in the brain
is sensitizing mice to this immediate rise in blood pressure with subcutaneous
AngII. Previous studies have shown that CaMKII can activate upstream
molecules, such as NADPH oxidase and in turn lead to increased generation of
reactive oxygen species which can then cause CaMKII oxidation thereby
sustaining CaMKII activity in vascular smooth muscle cells (225). In addition, it is
also possible that wt-CaMKIIα overexpression in the brain disrupts the blood
brain barrier integrity as a result of which AngII, immediately following the start of
infusion, can rapidly access cardiovascular control brain regions which are
otherwise protected by the blood brain barrier.
In summary, the experimental data presented herein provide new
evidence supporting neuronal CaMKIIα as an important downstream intermediate
in AngII-intraneuronal signaling and subsequent AngII-dependent hypertension.
More specifically, we showed that overexpression of wt-CaMKIIα exacerbates the
AngII-mediated inhibition of outward K+ current. Additionally, wt-CaMKIIα
overexpression in the brain subfornical organ potentiates both the acute central
and the chronic subcutaneous AngII-induced hypertension in mice. These set of
data led us to examine the effect of mutating redox-sensitive residues in CaMKIIα
on the AngII-mediated inhibition of neuronal K+ current and AngII-dependent
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hypertensive response as discussed in the next chapter.
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Chapter IV: Mutation of CaMKIIα at Cys280-Met281 attenuates the
potentiated Angiotensin II intra-neuronal signaling mechanisms mediated
by wild-type CaMKIIα overexpression

Introduction
Our wild-type CaMKIIα (wt-CaMKIIα) studies (Chapter III) indicated that
overexpression of wt-CaMKIIα exacerbated the AngII-mediated inhibition of K+
current in CATH.a neurons. Overexpressing wt-CaMKIIα in the brain subfornical
organ (SFO), an important cardiovascular regulatory brain nuclei, also
potentiated the acute AngII-mediated increase in blood pressure response
(Figure 3.8 Chapter III). Interestingly, in an AngII-infusion hypertensive model, wtCaMKIIα overexpression sensitized mice to an immediate increase in blood
pressure at an initial subpressor dose of subcutaneous AngII. Previous studies
have shown the importance of the SFO in AngII-mediated hypertension and
overexpression of copper zinc superoxide dismutase (CuZnSOD) in the SFO
attenuates the AngII-mediated increase in blood pressure in mice (90). These
studies therefore indicate the importance of CaMKIIα in mediating AngII-signaling
in neurons and the AngII-hypertensive response. However, the exact mechanism
by which AngII-mediated increase in ROS regulate CaMKIIα in neurons is still
unknown.
Past studies have extensively investigated AngII intra-neuronal signaling
mechanisms both in primary neurons from rat hypothalamus and brain, and also
in cultured neurons. Their studies showed that AngII stimulation inhibits K +
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current thus increasing neuronal firing frequency (80, 81, 226). However, when
they used inhibitors to inhibit signaling proteins, such as CaMKII and protein
kinase C (PKC) the AngII-mediated effects could be significantly blunted thereby
suggesting a role of CaMKII and PKC in AngII-signaling in central neurons (80,
81, 219). In addition to neurons, CaMKII in the cradiomyocytes (CaMKIIδ) has
also been illustrated in AngII-mediated ischemic stress response and apoptosis
in the heart. Importantly, Erickson et al. showed that in presence of AngII
stimulation and increased ROS CaMKIIδ undergoes oxidation in a paired
methionine residue (M281/282) (181, 220). Although Ca2+/CaM is required for the
initial activation of CaMKII yet oxidation in methionine 281/282 sustains CaMKIIδ
activity when the Ca2+ stimulus has subsided and the Ca2+/CaM has dissociated.
Whereas CaMKIIδ along with CaMKIIβ and CaMKIIγ have the paired methionine
residues at positions 281 and 282, the predominant brain isoform of CaMKII
(CaMKIIα) instead has a cysteine and methionine at 280 and 281 respectively. In
order to demonstrate that CaMKIIα is also susceptible to oxidation Erickson and
colleagues purified CaMKIIα and exposed to pro-oxidant conditions. They further
mutated the first methionine of CaMKIIδ with a cysteine to mimic CaMKIIα.
Interestingly, in presence of H2O2 purified CaMKIIα had increased oxidation
thereby suggesting the redox-sensitivity of CaMKIIα. Redox-regulation of
CaMKIIα has also been demonstrated by a nitric oxide (NO)-induced Snitrosylation of CaMKIIα in excitotoxic neuronal cell death mechanisms (189). In
this study, Coultrap et al. showed that NO generates autonomous CaMKIIα
activity by promoting S-nitrosyltion of cysteine 289 in addition to cysteine 280.
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Inhibition of S-nitosylation in either of those residues abolished CaMKIIα
autonomy and prevented the NO-induced excitotoxic neuronal cell death.
Additionally, in hippocampal neurons large increases in cytosolic Ca 2+ has been
associated with mitochondrial O2- generation which in turn activates protein
kinases, such as CaMKII (190). Activation of CaMKII by mitochondrial O2- is
mediated at least in part by inhibition of inactivating protein phosphatases, such
as protein phosphatase 2A (PP2A) and protein phosphatase 1 (PP1). Taken
together, these studies suggest the importance of redox regulation of different
CaMKII isoforms in a variety of pathological conditions (227).
In the present study we tested the hypothesis that mutation of redoxsensitive cysteine and methionine residues in CaMKIIα (C280A/M281V)
attenuates the AngII-mediated inhibition of neuronal K+ channel current and the
AngII-induced hypertensive response in mice. We show that mut-CaMKIIα
attenuates the potentiated AngII response following wt-CaMKIIα overexpression
in CATH.a neurons. In addition, mut-CaMKIIα in the brain prevents the
sensitization mechanism following AngII infusion as observed with wt-CaMKIIα
overexpression.

Experimental Methods
CATH.a neuronal cell culture
For detailed descriptions of mouse CATH.a neuronal cell culture and
differentiation, see experimental methods in Chapter II.
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Site-directed mutagenesis and mutant CaMKIIα adenovirus generation
Replication-deficient recombinant adenovirus (Ad5-CMV) encoding mouse
mutant calcium/calmodulin-dependent protein kinase IIα (mut-AdCaMKIIα) was
generated. Primer sequences were made specifically to mutate cysteine 280 to
alanine and methionine 281 to valine with overlapped extension polymerase
chain reaction (PCR). Briefly two sections of the wt-CaMKIIα plasmid (Origene)
were amplified by conventional PCR using HotStart PCR Master Mix (Qiagen,
Venlo, Limburg) with the following two set of primers: Section 1 forward 5’- GAA
TTC ATG GCT ACC ATC ACC TGC ACC C – 3’; reverse 5’ – CCA CGG TCT
CCT GTC TGT GCA - 3’. Section 2 forward 5’- GTG CAC AGA CAG GAG ACC
ACC GTG – 3’; reverse 5’ – GGA TCC TCA ATG CGG CAG GAC GGA - 3’. For
description on cloning using pJet1.2 PCR clone jet kit (Thermo Scientific) and
bacterial colony culture see experimental methods in Chapter III. Adenoviral
vectors encoding mut-CaMKIIα were constructed, purified and provided by the
University of Iowa Gene Vector Core as previously described (83, 221).
RNA extraction, cDNA and quantitative real-time RT-PCR
CaMKII mRNA levels were measured in CATH.a neurons following adenovirusmediated transduction of mut-CaMKIIα. Real-time RT-PCR was utilized as
previously described in experimental methods of Chapter III. mRNA levels of
voltage-dependent K+ channels, such as Kv2.1, Kv2.2, Kv4.2 and Kv4.3 were also
detected in CATH.a neurons following adenoviral transduction. To confirm the
overexpression of CaMKIIα in mouse brain following intracerebroventricular (ICV)
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injections, micro punches of the SFO along with ventricular tissues were
collected and then RNA was extracted in Trizol reagent.
Western blot analysis
Total and phosphorylated CaMKIIα protein expression was detected in CATH.a
neurons following adenoviral transduction at different multiplicity of infection. For
description of Western blotting protocol, see experimental methods in Chapter III.
Electrophysiological record of voltage-gated K+ currents
For description of whole-cell patch-clamp technique to record voltage-gated K+
current, see experimental methods in Chapter III. Voltage-gated K+ currents were
recorded in non-transduced, AdEmpty (25MOI), wt-AdCaMKIIα (25MOI) and mutAdCaMKIIα (25MOI) at baseline and following 5 minutes of AngII (100 nM)
superfusion. To confirm the AngII-mediated response on K+ channel currents,
AngII was washed out and K+ current was recorded for 15 minutes.
In vivo mouse studies – radiotelemetry implantation,
intracerebroventricular cannula placement and osmotic minipump
implantation
All animal procedures were performed as described in experimental methods of
Chapter III, in accordance with Guidelines for the Care and Use of Experimental
Animals of the American Physiological Society and the National Institutes of
Health, with specific experimental protocols being reviewed and approved by the
University of Nebraska Medical Center Institutional Animal Care and Use
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Committee. Mice received left carotid artery radiotelemeters to measure
cardiovascular parameters such as mean arterial pressure, systolic pressure,
diastolic pressure, heart rate and pulse pressure. Cannulas were implanted
intracerebroventricularly to inject control adenovirus (AdGFP) and mut-CaMKIIα
adenovirus. Both the adenoviruses were injected at 5 x 10 7 plaque forming units.
It is to be noted that mice for these set of in vivo studies did not receive central
acute AngII injections. ICV adenovirus injections were followed by saline and
AngII subcutaneous osmotic minipump implantation to establish the AngII-infused
mouse model of hypertension. The slow pressor dose infusion rate of 400
ng/kg/min was selected, as previously detailed in Chapter III Methods.
Immunohistochemistry
Mouse brains were collected 7 days post-ICV AdGFP or mut-AdCaMKIIα
injections and 20 µm sections of the brains were prepared using a cryostat (Leica
CM3050S). The sections were incubated at 4 ºC overnight with a rabbit primary
antibody against CaMKIIα (1:200, abcam) and a rabbit P-CaMKIIα (1:200,
abcam) prepared in 0.1 M PB containing 2% NHS and 0.3% Triton X-100. Alexa
Fluor 598 secondary antibody (1:200, Invitrogen) was then used to incubate the
brain sections at room temperature for 2 hours. Fluorescent images of the
subfornical organ and ventricles were detected by confocal laser scanning
microscopy (Zeiss LSM 510 Meta Confocal Microscope) at 20X and 40X
magnification. For detailed immunohistochemical staining procedure, see
experimental methods in Chapter III.
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Statistical Analysis

All data are presented as means ± standard error of the mean (SEM). Data were
analyzed by Student’s t-test for two group comparisons or by ANOVA with
Newman Kewls post-hoc test. P-value less than 0.05 was considered statistically
significant. Statistical analyses were performed using GraphPad Prism 5.0
statistical and graphical software.
Results

Adenoviral-mediated transduction of mut-CaMKIIα increases total and
phosphorylated CaMKIIα protein in CATH.a neurons
To check if the mut-CaMKIIα adenovirus expresses CaMKIIα protein, we first
detected total CaMKIIα protein expression in non-transduced CATH.a neurons
and neurons transduced with AdEmpty and mut-AdCaMKIIα at 10, 25 and
50MOI. CaMKIIα protein was significantly overexpressed in all the mutAdCaMKIIα transduced groups (Figure 4.1A,B); however, in order to be
consistent with our wt-CaMKIIα in vitro studies we selected the 25MOI of the
adenovirus for the next set of cell culture experiments. Phosphorylated CaMKIIα
levels were also increased in CATH.a neurons transduced with mut-CaMKIIα
adenovirus as compared to the non-transduced and AdEmpty-transduced
neurons (Figure 4.1A,C). To determine mRNA levels of CaMKIIα we utilized realtime RT-PCR in CATH.a neurons following 25MOI mut-AdCaMKIIα transduction.
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Primers specific for CaMKIIα revealed a significant increase in CaMKIIα mRNA in
CATH.a neurons transduced with mut-CaMKIIα adenovirus (Figure 4.1D). The
other CaMKII isoforms, such as CaMKIIβ and CaMKIIδ did not change
significantly in between the non-transduced, AdEmpty, and mut-AdCaMKIIα
groups (Figure 4.1 E, F). Kinase activity assay was utilized to measure CaMKII
activity in AdEmpty (25MOI) and wt-AdCaMKIIα (25MOI) and mut-AdCaMKIIαtransduced CATH.a neurons. Neurons with wt-CaMKIIα overexpression had 3fold higher activity as compared to AdEmpty-transduced neurons. CaMKII activity
in mut-AdCaMKIIα group was lower than wt-CaMKIIα transduced neurons but
higher than AdEmpty-transduced neurons (Figure 4.1G) (n = 2).
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Figure 4.1. Transduction of mut-AdCaMKIIα causes significant upregulation
of CaMKIIα expression in CATH.a neurons. (A) Representative Western blot
analysis of CATH.a neuronal cell lysates probed for primary antibody against total
and phosphorylated CaMKIIα; Summary densitometry data of Western blot
analysis showing levels of (B) CaMKIIα and (C) P-CaMKIIα in non-transduced,
AdEmpty (10, 25 and 50 MOI)- and mut-AdCaMKIIα (10, 25 and 50 MOI)transduced neurons; Real-time RT-PCR data with primers specific for CaMKIIα
(D), CaMKIIβ (E), and CaMKIIδ (F) genes normalized to 18s rRNA and
expressed as fold control. (G) CaMKII activity in AdEmpty (25MOI) and wtAdCaMKIIα (25MOI) and mut-AdCaMKIIα-transduced neruons as measured by
kinase activity assay and reported as fold change from control. *P<0.05 vs. nontransduced and AdEmpty.
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AngII-mediated increased inhibition of K+ current following wt-CaMKIIα
overexpression is rescued in mut-CaMKIIα-transduced CATH.a neurons
Whole-cell configuration of the patch-clamp technique was utilized to record
voltage-gated K+ current (Ikv) in non-infected and adenovirus transduced CATH.a
neurons at baseline and following 5 minutes of AngII (100 nM) superfusion.
Neurons transduced with mut-CaMKIIα adenovirus showed similar percent
inhibition (13%) in Ikv when compared to non-transduced (16%) and AdEmpty
(16%)-transduced CATH.a neurons (Figure 4.2). Interestingly, when compared to
wt-CaMKIIα data as presented in Chapter III (37% inhibition of outward K +
current) the restoration in the AngII-mediated reduction in Ikv with mut-CaMKIIα
was significant. Both transient and steady-state K+ current followed a similar
pattern. To note, the Ikv data in the non-transduced, AdEmpty and wt-AdCaMKIIα
groups are similar to those in Chapter III results.
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Figure 4.2. Mut-CaMKIIα transduction restores the potentiated AngIImediated inhibition of outward K+ current in CATH.a neurons. Percent
inhibition of outward K+ current following 5 minutes of AngII (100 nM) superfusion
in non-transduced, AdEmpty (25MOI) or mut-AdCaMKIIα (25 MOI)-transduced
CATH.a neurons (n = 4-7 biological replicates for all experimental groups). *P <
0.05 vs. non-transduced. #P < 0.05 vs. wt-AdCaMKIIα.
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Mutant CaMKIIα transduction does not change mRNA levels of voltagedependent K+ channels in CATH.a neurons
To determine the outcome of mut-CaMKIIα expression on voltage-dependent K+
channels, real-time RT-PCR was utilized to measure mRNA levels of Kv2.1, Kv2.2,
Kv4.2 and Kv4.3 in CATH.a neurons. Baseline expression of the channels was
detected in AdEmpty (25MOI) and mut-AdCaMKIIα transduced neurons. Initial
experiments showed a modest decrease in Kv2.1, and Kv4.2 and Kv4.3 mRNA
expression in mut-CaMKIIα transduced neurons as compared to AdEmpty;
however, the data did not reach statistical significance. Surprisingly Kv2.2 mRNA
levels were modestly increased with mut-CaMKIIα expression (Figure 4.3).
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Figure 4.3. Mut-CaMKIIα modestly decrease mRNA expression of voltagedependent K+ channels in CATH. neurons. Quantitative real-time PCR
analysis showing (A) Kv2.1, (B) Kv2.2, (C) Kv4.2 and (D) Kv4.3 mRNA levels in
AdEmpty (25MOI) and mut-AdCaMKIIα (25MOI) transduced CATH.a neurons.
n=2 biological replicates in all experimental groups.

117

Intracerebroventricular injections of mut-CaMKIIα adenovirus increases
CaMKIIα expression in brain subfornical organ of mice
Mice were implanted with ICV cannulas to receive central injections of AdGFP
and mut-AdCaMKIIα adenovirus. The expression of CaMKIIα in the brain SFO
was confirmed by immunohistochemistry 7 days post ICV adenovirus injections.
CaMKIIα was greatly increased in mice receiving mut-CaMKIIα adenovirus as
compared to AdGFP group (Figure 4.4A). Interestingly, levels of P-CaMKIIα did
not increase as seen in our previous studies with wt-CaMKIIα overexpression in
the SFO (Figure 4.4A). CaMKII mRNA levels were also detected by real-time RTPCR in brain SFO micropunches following ICV adenovirus injections. The mRNA
level for CaMKIIα was significantly increased by ~12 fold in mice receiving mutCaMKIIα injections (Figure 4.4B). Interestingly, another CaMKII isoform
(CaMKIIβ), which has a wide tissue distribution and is also present in the brain,
was increased by 3 fold. The mRNA levels of other CaMKII isoforms (CaMKIIδ
and CaMKIIγ) did not change between the groups.
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Figure 4.4. Adenoviral-mediated overexpression of CaMKIIα in the
subfornical organ (SFO). (A) Representative confocal microscopy images
showing expression of GFP, CaMKIIα and P-CaMKIIα in SFO of mice 1 week
after intracerebroventricular (ICV) injection of AdGFP or mut-AdCaMKIIα.
Coronal brain sections (20 µm) were stained for GFP (green), total and
phosphorylated CaMKIIα (red). (B) Real-time PCR data showing relative mRNA
expression of CaMKIIα, CaMKIIβ, CaMKIIδ and CaMKIIγ genes in brain
micropunches. Values are normalized to 18S rRNA and expressed as relative to
control. Scale bar = 100 µm
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Mutant CaMKIIα expression in the brain subfornical organ prevents the
sensitization mechanism following AngII infusion
Mice received ICV injections of AdGFP or mut-CaMKIIα adenovirus prior to
minipump implantation. Baseline blood pressure was recorded with
radiotelemetry for 3 days following which subcutaneous saline and AngII osmotic
minipumps were implanted. Interestingly, mice which received ICV mutAdCaMKIIα had a modest increase in blood pressure on days 1-2 after AngII
infusion but declined to near baseline levels on day 3. Blood pressure then
gradually increased in mice receiving mut-AdCaMKIIα with AngII infusion (Figure
4.5A). This increase in mean arterial pressure (MAP) was similar to the AdGFP
mice with AngII infusion and is characteristic of the slow-pressor AngIIhypertensive model (222, 223). The peak AngII response on days 15-17 was lower
in mut-AdCaMKIIα group (115 mmHg) as compared to the AdGFP group (125
mmHg). Importantly, when compared to the wt-CaMKIIα data (peak AngII
response – 133 mmHg), as presented in results of Chapter III, the peak AngII
response is significantly attenuated in the mut-AdCaMKIIα group and the
sensitization mechanism that is seen immediately following AngII infusion in the
wt-CaMKIIα overexpression mice is prevented with mut-CaMKIIα expression.
Blood pressures came back to baseline levels on day 22-23 for each group when
the minipumps were empty. Systolic and diastolic blood pressures followed a
similar pattern as the MAP (Figure 4.5C, D). Heart rate did not differ between the
groups (Figure 4.5B).
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Figure 4.5. Intracerebroventricular injection of mut-CaMKIIα in the brain
and chronic infusion of subcutaneous AngII via osmotic minipumps.
Representative line graphs showing (A) mean arterial pressure, (B) heart rate,
(C) systolic blood pressure, and (D) diastolic blood pressure and via
radiotelemetry in C57BL/6 mice at baseline, following intracerebroventricular
injection of AdGFP or mut-AdCaMKIIα, and after subcutaneous implantation of
osmotic minipumps set to release saline or AngII (400 ng/kg/min). *P < 0.05 vs.
wt-AdCaMKIIα mice with AngII infusion and #P < 0.05 vs. AdGFP mice with AngII
infusion . n = 6-9 mice for each experimental group.
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Discussion
Calcium/calmodulin-dependent protein kinase II (CaMKII) belongs to a
multifunctional family of serine/threonine protein kinases. Different isoforms of
CaMKII have diverse roles and distribution and their function is often determined
by the tissues in which they are expressed. For examples, numerous studies
have shown that CaMKII in neuronal tissues play important role in memory and
synaptic plasticity (228). On the other hand, in T lymphocytes, CaMKII have a
major role in regulation of CD8 T cell proliferation, cytotoxic effector function and
response to re-stimulation (228). In central neurons, the AngII-mediated
regulation of ion channels has elucidated the involvement of CaMKII as a
downstream signaling molecule in AngII-intraneuronal signaling pathways (80,
219). Additionally, increased reactive oxygen species (ROS) can also act as
signaling intermediates in AngII signaling pathway in neurons. However, the
exact mechanism by which AngII and increased ROS regulates CaMKII in
neurons, specifically the major neuronal isoform of CaMKII (CaMKIIα) is unclear.
In the present study we report that: (1) mutation of redox-sensitive cysteine and
methionine residues in CaMKIIα restores the potentiated AngII-mediated K+
current inhibition, (2) intracerebroventricular injection of mutant CaMKIIα
adenovirus in brain subfornical organ of mice prevents the initial sensitization
following AngII infusion, and (3) mutant CaMKIIα expression in the brain
significantly attenuates the AngII-induced peak rise in blood pressure as
compared to wt-CaMKIIα overexpressed mice.
Previous studies by Erickson et al. demonstrated that in the heart
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CaMKIIδ undergoes oxidation in paired methionine residues (met 281/282)
present in the regulatory domain (181). Oxidation in methionine residues sustain
CaMKIIδ oxidation in absence of Ca2+/CaM. They further showed that AngIIinduced CaMKIIδ oxidation leads to cardiomyocyte apoptosis. However, neuronal
CaMKIIα differs from the other CaMKII isoforms because of the presence of a
cysteine and methionine in positions 280 and 281 respectively. Importantly, in
presence of increased mitochondrial superoxide, CaMKII in hippocampal
neurons have increased kinase activity (190). This increase in CaMKII activity is
mediated at least in part by inhibition of protein phosphatases that regulate
CaMKII autophosphorylation state. Moreover, recent studies by Coultrap and
Bayer demonstrated that in addition to oxidation, cysteine residues in CaMKIIα
are also susceptible to nitric oxide-mediated S-nitrosylation (189). In their study
they investigated the susceptibility of two cysteines at positions 280 and 289 to
S-nitrosylation and showed that mutation of either cysteine prevents NO-induced
excitotoxic neuronal cell death. Although these studies indicate the redoxsensitivity of CaMKIIα, we wanted to specifically determine the outcome of
mutating C280/M281of CaMKIIα on AngII-intraneuronal signaling mechanisms.
Furthermore, we wanted to compare the effect of CaMKIIα mutation with our wtCaMKIIα overexpression studies by looking at AngII-mediated K+ current
inhibition and the AngII-induced hypertension.
First, we wanted to investigate the effect of mut-CaMKIIα on AngIImediated inhibition of K+ current. Voltage-dependent K+ current (Ikv) was
measured in mouse CATH.a neurons either non-infected or transduced with
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AdEmpty and mut-CaMKIIα adenovirus at 25MOI. Interestingly, the percent
inhibition of Ikv in all the three groups was approximately similar with a modest
decrease observed in mut-CaMKIIα transduced neurons. However, when
compared with the wt-CaMKIIα data from Chapter III, it is evident that the
exacerbated AngII-mediated inhibition of Ikv with wt-CaMKIIα overexpression is
restored with mutation of CaMKIIα. Importantly, as previously mentioned in
Chapter III discussion, CATH.a neurons do not appear to have endogenous
CaMKIIα and this may explain why CaMKIIα mutation does not completely
abolish the AngII-mediated Ikv inhibition. Other protein kinases, such as PKC or
CaMKIIβ may play a role in mediating AngII-downstream signaling in CATH.a
neurons. These studies therefore confirm that redox-regulation of CaMKIIα plays
an important role in AngII-signaling in central neurons.
Since wt-CaMKIIα overexpression elucidated a potential compensatory
mechanism in the transcriptional upregulation of different voltage-dependent K+
channels, we wanted to determine whether mut-CaMKIIα has any role in the
regulation of these channels. To do that, we utilized real-time RT-PCR and
measured mRNA levels of Kv2.1, Kv2.2, Kv4.2 and Kv4.3 in CATH.a neurons
transduced with either AdEmpty or mut-AdCaMKIIα. From these initial studies we
observed that there was no significant different in mRNA expression of any of the
channels between the two groups. This data once again confirms the
compensatory mechanism that overexpression of wt-CaMKIIα lowers baseline Ikv
which then leads to the transcriptional upregulation of these channels.
We next wanted to evaluate the role of ICV mut-CaMKIIα injection on
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chronic subcutaneous AngII infusion and the AngII-induced hypertensive
response in mice. Consistent to wt-CaMKIIα overexpression ICV mut-CaMKIIα
did not alter baseline blood pressure and heart rate. Intriguingly we observed a
similar rise in blood pressure in mut-AdCaMKIIα injected mice for 2 days
immediately after the start of AngII infusion as observed with wt-CaMKIIα mice.
However, blood pressure came back to baseline levels after 2 days of AngII
infusion and continued to rise gradually as AdGFP mice infused with AngII. This
is the characteristic slow pressor chronic AngII-induced hypertensive model that
has been extensively used by our lab and others to study AngII-mediated
neurogenic hypertension. We speculate that the immediate increase in blood
pressure in mice with mut-CaMKIIα occurs as a result of some forms of active
CaMKIIα already present in the brain other than oxidized form. This can happen
as a result of autophosphorylation of CaMKIIα in threonine 286 residue and can
prolong CaMKIIα activity in absence of Ca2+/CaM. However, with increase in
AngII levels in the brain and the increase in reactive oxygen species, mutCaMKIIα is prevented from being oxidized as opposed to wt-CaMKIIα. This in
turn prevents the sustained CaMKIIα activation and the rise in blood pressure
follows the characteristic pattern of slow-pressor AngII-induced hypertension.
Since recent studies have indicated potential S-nitrosylation of CaMKIIα in
cysteine 280/289 (199), it would be interesting to see if mutation of cysteine 289
in addition to the C280/M281 can further attenuate the AngII-induced peak
increase in blood pressure and whether it would have an effect on the initial rise
in blood pressure with AngII infusion.
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In summary, the experimental data presented herein provide important
insight on the role of redox-sensitive CaMKIIα in AngII-intraneuronal signaling
and subsequent AngII-dependent hypertension. More specifically, we showed
that mutation of CaMKIIα at cysteine 280 and methionine 281 restores the
exacerbated AngII-mediated inhibition of outward K+ current observed with wtCaMKIIα overexpression. Additionally, mut-CaMKIIα in the brain subfornical
organ prevents the early sensitization mechanism and lowers the peak AngIIresponse in a slow-pressor AngII-hypertensive model. In conclusion these
studies may help to identify potential therapeutic targets, such as CaMKIIα, in the
treatment of neuro-cardiovascular diseases, such as hypertension and heart
failure.
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Chapter V: Conclusion
Overall summary of findings and discussion
Dysregulation of angiotensin II (AngII) signaling in the central nervous system
(CNS) is involved in the pathogenesis of cardiovascular disorders, including
hypertension and heart failure (73, 89, 214, 229). Several components of the
renin-angiotensin system (RAS) including AngII have been shown to be elevated
both in periphery as well as in the brain during these diseases (87, 88, 191).
Numerous studies so far have investigated the AngII-intraneuronal signaling
mechanisms associated with the pathogenesis of hypertension and heart failure.
One such mediator of AngII signaling in neurons is reactive oxygen species
(ROS) (56, 90, 112, 139, 230). Imbalance between the ROS producing
components and the antioxidant defense mechanisms can lead to downstream
pathological responses of AngII (96, 110).By acting on the type 1 receptor (AT1R)
AngII leads to physiological responses such as vasoconstriction, sympathetic
nervous system activation, sodium and water reabsorption, vascular and cardiac
remodeling, inflammation, fibrosis, thrombosis, and release of aldosterone (ALD),
and vasopressin (AVP) (10, 22). Clinically, the common therapeutics used for the
treatment of diseases, like hypertension, consist of RAS blockers, such as
angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers
(ARBs) in addition to β-adrenergic receptor blockers (β-blockers) (231). However,
according to a report released by the Center for Disease Control and Prevention
(CDC) in 2012, inspite of taking the above mentioned medications, approximately
34% of the hypertensive patients in the United States are unable to have their
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blood pressures controlled (7). Since enhanced activation of RAS and elevated
AngII levels in the brain are implicated in hypertension therefore it is of utmost
importance to understand the intracellular signaling mechanisms mediated by
AngII in neurons in order to identify novel therapeutic targets to treat neurocardiovascular diseases.
In AngII-stimulated central neurons, the two major sources of ROS
production are the nicotinamide adenine dinucleotide phosphate (NADPH)
oxidases (NOX) and the mitochondria (99, 103, 139). Both the sources primarily
lead to an increase in superoxide (O2-) and hydrogen peroxide (H2O2). In
addition to electron leakage from the mitochondrial electron transport chain
(ETC) leading to excessive ROS production (102, 103), recent studies from our
lab have shown that NOX localized in neuronal mitochondria can also increase
mitochondrial ROS levels (115). In addition, proinflammatory cytokines activated
by AngII signaling also generate ROS in the brain (109, 232). The increased O2can then regulate ion channels thereby modulating the channel currents to
increase neuronal firing rate and neuronal activation. For example, studies by
Sumners and colleagues have shown that in central neurons, AngII inhibits K +
current and this in turn leads to an increase in neuronal firing frequency (79-81).
Furthermore, our lab has showed that this reduction in K+ current mediated by
AngII can be attenuated by scavenging O2- with specific scavenging enzymes,
such as copper zinc superoxide dismutase (CuZnSOD) and manganese
superoxide dismutase (MnSOD) (83). Neuronal firing can also be increased by
the increase in Ca2+ current in AngII-stimulated neurons. AngII has indeed been
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shown to increase intracellular Ca2+ levels in a neuronal cell line (84).
Additionally, Sumners and Raizada have shown that the the AngII-mediated
reduction in K+ current and the increased neuronal firing frequency can be
attenuated by inhibiting some of the Ca2+ dependent enzymes, such as protein
kinase C (PKC) and calcium/calmodulin-dependent protein kinase II (CaMKII)
(80, 81).
In the brain AngII can activate neurons in the circumventricular organs
(CVOs), which abundantly express the AT1R (64, 75, 233). The CVOs are devoid
of an intact blood brain barrier (BBB) and is therefore exposed to circulating
peptides and hormones. One such CVO is the subfornical organ (SFO), which
lies in the roof of the third ventricle and is an important cardiovascular regulatory
brain nucleus (90, 110). The importance of SFO in AngII-mediated signaling was
shown by lesioning the SFO that abrogated the hypertensive response induced
by circulating AngII (45, 60). Furthermore, adenoviral-mediated overxpression of
CuZnSOD in the SFO scavenges the AngII-induced O2- and attenuates
sympathetic drive and blood pressure in numerous animal models of
hypertension (90).
The family of multifunctional calcium/calmodulin (Ca2+/CaM)-dependent
protein kinases (CaMKs) including CaMKI, CaMKII and CaMKIV modulate many
of the cellular responses to Ca2+. These downstream effector molecules translate
and co-ordinate the dynamic second messenger, Ca2+, into appropriate cellular
responses by a highly specific and reversible phosphorylation of a number of
substrate proteins in their serine or threonine residues. This family of protein

132

kinases has both common as well as unique features with respect to their
structure, regulation and activation. The CaMKII is responsible for the coupling of
Ca2+ increase to ion channel activation, gene transcription, neurotransmitter
synthesis and release, cytoskeletal organization and apoptosis (181-183).
Classically, CaMKII is activated by the binding of Ca2+/CaM followed by
autophosphorylation in the regulatory domain. Autophosphorylation confers the
kinase activity of CaMKII which can then phosphorylate specific serine and
threonine residues of target proteins. Active CaMKII is switched back to the
inactive resting form by dephosphorylation by specific phosphatases such as
protein phosphatase 1 (PP1) or protein phosphatase 2A (PP2A) (184186).Interestingly, recent studies have shown that the AngII-mediated
pathological responses in the heart involve a second mechanism of sustained
CaMKII activation under oxidant conditions which is independent of Ca2+/CaM.
More specifically, studies by Erickson et al. have demonstrated that oxidation of a
paired methionine residue (M281/282) in the cardiomyocyte isoform of CaMKII
(CaMKIIδ) is a downstream signal for AngII and ischemic stress response in the
heart and inhibition of CaMKIIδ protects the heart against AngII-mediated
apoptosis and other pathological myocardial responses (181, 187). Since, the
paired methionine residue is conserved in all three isoforms of CaMKII except the
predominant neuronal isoform of CaMKII (188) (CaMKIIα) (CaMKIIα has a
cysteine residue in position 280 instead of the first methionine of the pair), they
also generated a M281C mutant of CaMKIIδ and also purified CaMKIIα. Both
purified CaMKIIα and M281C mutant CaMKIIδ were activated by H2O2 indicating
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the importance of cysteine in ROS-dependent CaMKII activation. More recently, a
nitric oxide (NO)-mediated S-nitrosylation of CaMKIIα has been implicated in
excitotoxic neuronal cell death. The results from that study show that specific Snitrosylation of C280/289 generated autonomous activation of CaMKIIα
independent of Ca2+/CaM binding and mutation of either site protected from NOinduced neuronal cell death(189). The redox sensitivity of CaMKII has also been
illustrated in studies where large increases in cytosolic Ca2+ causes mitochondrial
O2- generation and upregulation of CaMKII in hippocampal neurons(190).
Activation of CaMKII by this mitochondrial-induced O2- is also mediated at least
in part by oxidative suppression of protein phosphatases that dephosphorylate
CaMKII. Studies by Yin et al. have also showed that in CATH.a neurons AngII
increases CaMKII phosphorylation, causing CaMKII activation, with a significant
increase observed after 5 minutes of AngII stimulation. However, neurons, which
were transduced with AdMnSOD (adenovirus overexpressing manganese
superoxide dismutase) had reduced CaMKII phosphorylation, indicating that
ROS is involved at least in past in mediating AngII-induced CaMKII activation in
central neurons (83). Although these studies convincingly demonstrate the redox
sensitivity of CaMKII in physiological and pathological responses, the specific
role of redox regulation of neuronal CaMKIIα in AngII-intraneuronal signaling and
the AngII-induced hypertensive response is unknown.
Considering the importance of AngII intra-neuronal signaling in the
pathogenesis of diseases including hypertension and heart failure, numerous
investigations are being carried out to date to better understand the precise
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signaling mechanisms both in vivo and in vitro. However, due to the technical
challenges in studying AngII-induced intra-neuronal signaling in vivo in animal
models of hypertension and heart failure as discussed in Chapter II, neuronal cell
culture models have been frequently utilized to examine the specific intraneuronal signaling pathways induced by AngII (80, 86). Nevertheless, there are
also limitations in using neuronal cell culture models to recapitulate the AngII
intra-neuronal signaling events occurring in vivo such as: 1) neuronal cells are
often immortalized and/or isolated from a tumor; 2) cells are usually cultured in a
hyperoxic environment (i.e. 21% oxygen) as compared to their in vivo
environment (1-4% oxygen); and 3) the lack of neighboring glia and endothelial
cells may alter a particular response in the cultured neurons that would normally
occur in vivo. A fourth limitation in using neuronal cell culture models as it
specifically relates to understanding AngII intra-neuronal signaling is the lack of
evidence indicating the stability of exogenous AngII in neuronal cell culture
media. Many studies have examined intra-neuronal responses, such as changes
in mRNA levels and protein expression, 1-48 hours after a single administration
of exogenous AngII into the neuronal cell culture media (200-202). Data from
these studies are often interpreted to indicate that the observed changes are also
occurring in neurons of various hypertensive and heart failure models in which
circulating and/or brain levels of AngII are chronically elevated (203, 204).
However, it remains unclear if a single treatment of exogenous AngII given to
neurons in culture results in a chronic elevation of AngII levels in the media.
Therefore, considering our ultimate goal of studies to understand AngII-
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intraneuronal signaling, we began by measuring levels of AngII in our CATH.a
neuronal cell culture media following a single AngII (100 nM) administration.
Using liquid chromatography and tandem mass spectrometry, we were able to
detect AngII levels in culture media. Importantly, AngII declined to near basal
levels 3 hours post the single exogenous AngII administration. Levels of two of
the AngII metabolites, AngIII and Ang1-7 modestly, but significantly increased in
the media after 15-60 minutes of AngII administration. Furthermore, replenishing
the neuronal media with fresh AngII every 3 hours resulted in chronically elevated
levels of AngII. It should be noted that as a result of differential expression of
AngII receptors and other components of the RAS, the stability of exogenous
AngII in cultured media will be drastically different in various cell types. In
addition, enzymes involved in AngII metabolism, such as aminopeptidase A
(APA) and angiotensin converting enzyme 2 (ACE2) may also have different
expression levels depending on the cell type thereby influencing AngII stability in
the media.
Next, to determine the redox-regulation of CaMKIIα and its role in
AngII-signaling in neurons, we compared adenoviral-mediated overexpression of
wild-type CaMKIIα (wt-CaMKIIα) to an oxidation-resistant mutant CaMKIIα (mutCaMKIIα) in modulating AngII-regulated neuronal K+ channel current and the
AngII-induced neurogenic hypertension in mice. In an attempt to determine the
functional relevance of overexpressing wt-CaMKIIα on AngII-signaling in
neurons, we cloned the wt-CaMKIIα gene and an adenovirus (wt-AdCaMKIIα)
was generated in the University of Iowa Viral Vector Core Facility. To begin our
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studies, we confirmed the adenovirus-mediated overexpression of total and
active wt-CaMKIIα protein with increasing multiplicity of infection (MOI) in
CATH.a neurons. Both 25MOI and 50MOI of the adenovirus transduction yielded
significant overexpression of total and phosphorylated (active) wt-CaMKIIα
protein as detected by Western blot analysis. It should be noted that in order to
avoid any cytotoxicity with a higher MOI of adenovirus, all the subsequent in vitro
cell culture experiments were done in the presence of 25MOI of wt-AdCaMKIIα.
Wt-CaMKIIα was also transcriptionally upregulated as evident by the mRNA
levels measured by RT-PCR. We also looked for transcriptional upregulation of
other CaMKII isoforms following overexpression of wt-CaMKIIα. However, mRNA
levels of the other CaMKII isoforms did not change confirming the specificity of
the adenovirus for CaMKIIα. To note, although CaMKIIα is predominantly present
in neurons; however, CATH.a neurons have very little to non-detectable levels of
basal CaMKIIα as compared to the other CaMKII isoforms as evident by the very
high cycle number in the RT-PCR analysis (Chapter III). Thus, CATH.a neurons
serve as an appropriate cell culture model to study the role of CaMKIIα in
mediating the downstream signaling effects of AngII in neurons. However, the
presence of other CaMKII isoforms should also be considered while analyzing
some of the AngII data in CATH.a neurons.
We next set out to examine the effect of wt-CaMKIIα overexpression on
the AngII-mediated inhibition of K+ current. To perform these set of experiments
we collaborated with Dr. Yulong Li and his lab in the department of Cellular and
Integrative Physiology at UNMC. Whole-cell configuration of the patch-clamp
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technique was used to record voltage-gated K+ current in differentiated mouse
CATH.a neurons at baseline and post 5 minutes of AngII superfusion. K + current
was also measured after AngII washout for 15 minutes in order to confirm the
changes observed with AngII superfusion. The percent inhibition in peak and
steady-state K+ current following AngII stimulation was approximately 16% in
both non-transduced and AdEmpty-transduced CATH.a neurons. However, in
neurons where wt-CaMKIIα was overexpressed, the AngII-mediated percent
inhibition in K+ current was almost 37%, which is significantly higher than the
non-transduced and AdEmpty group. Baseline K+ current was also modestly
lower in the wt-AdCaMKIIα-transduced CATH.a neurons as compared to the
other two groups. Simultaneous experiments were performed where K + current
was recorded in the three groups in the presence of a CaMKII inhibitor, KN-93.
Neurons were pretreated with KN-93 for 30 minutes and then baseline current
was measured followed by AngII superfusion and washout. Interestingly, the
AngII-mediated percent inhibition in K+ current was completely abolished in all
the three groups when pretreated with KN-93.
It is important to consider that the presence of other CaMKII isoforms
in CATH.a neurons, as demonstrated by the mRNA data, may account for the
AngII-mediated reduction in K+ current in the non-transduced and AdEmptytransduced neurons. Moreover, as illustrated by previous studies that PKC is also
involved in the AngII-intraneuronal signaling (80, 81), we speculate that CATH.a
neurons may have basal PKC levels which contribute to the AngII-regulation of
neuronal ion channels. Furthermore, since KN-93 is a non-specific inhibitor of
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CaMKII, it can inhibit different CaMKII isoforms in CATH.a neurons thereby
completely attenuating the AngII response in all the three groups. Taken together,
these studies identified CaMKIIα as one of the mediators of AngII signaling and
its involvement in the exacerbated reduction of K+ current in AngII-stimulated
neurons.
To determine the causal relationship between overexpression of wtCaMKIIα and the significant reduction in K+ current in CATH.a neurons, we
sought to detect the mRNA expression of specific voltage-dependent K+ channels
which have previously been shown to be present in important autonomic regions
of the brain and also involved in AngII signaling in neurons (85, 224, 234).
Surprisingly, wt-CaMKIIα overexpression modestly but not significantly increased
the basal mRNA expression of Kv2.1, Kv2.2, Kv4.2 and Kv4.3 as compared to nontransduced or AdEmpty-transduced groups. We speculate that transcriptional
increase in Kv channels may act as a compensatory mechanism to
counterbalance the reduction in K+ current following wt-CaMKIIα overexpression
in CATH.a neurons. It is also important to consider that the protein expression of
these voltage-dependent K+ channels was not examined. Moreover, the cellular
localization of these voltage-gated channels is crucial for their function and
transcriptional up regulation does not necessarily indicate increased membrane
localization.
We next investigated the outcome of wt-CaMKIIα overexpression in
mouse brain on the acute central AngII-induced pressor response. To compare
the acute central AngII response pre and post-adenovirus injection we initially
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injected AngII (350 ng) intracerebroventricularly (ICV) to specifically target the
SFO. Central AngII injections elicited the characteristic rapid transient increase in
blood pressure. Interestingly, 3 days post ICV adenovirus injections the central
acute AngII-induced rise in blood pressure was significantly potentiated in wtCaMKIIα overexpressed mice as compared to AdGFP injected mice. In addition
to the increased peak changes in mean arterial pressure (MAP), the duration of
the AngII-response was also greater in wt-CaMKIIα overexpressed group. To
confirm CaMKIIα overexpression in the SFO, we stained mouse brain sections
for total and phosphorylated CaMKIIα protein and found a prominent increase in
CaMKIIα expression in the SFO. These data indicate that overexpression of wtCaMKIIα in the SFO greatly potentiates the central acute AngII-mediated
changes in blood pressure. We speculate that since CaMKIIα acts as a
downstream molecule of AngII signaling in neurons, therefore increasing wtCaMKIIα expression will enhance the effects mediated by AngII on neurons,
including reduction in K+ current and an increase in neuronal firing thereby
leading to the rapid increase in blood pressure.
Whereas the central AngII studies implicate the importance of wtCaMKIIα in the brain, to correlate it clinically with human essential hypertension,
the functional relevance of wt-CaMKIIα overexpression in the brain was
evaluated following chronic subcutaneous AngII infusion via osmotic minipumps.
For these experiments mice received ICV injections of GFP and wt-CaMKIIα
adenovirus following which osmotic minipumps were implanted to
subcutaneously infuse chronic AngII (400 ng/kg/min). Mice which received
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AdGFP injections showed the characteristic chronic AngII-induced increase in
mean arterial pressure with a peak change of 31 mmHg. This gradual increase in
blood pressure resembles the slow-pressor AngII-induced hypertensive model
and closely correlates with human hypertension. Interestingly, mice with wtCaMKIIα overexpression had a significant increase in blood pressure
immediately following AngII minipump implantation and continued to rise over the
course of AngII infusion with a peak change of 39 mmHg. We posit that
overexpression of wt-CaMKIIα in the brain sensitized these mice to an immediate
increase in blood pressure at an initial subpressor dose of subcutaneous AngII.
There could be several possible explanations for this phenomenon. As discussed
with the acute AngII data, overexpression of a downstream signaling molecule,
such as wt-CaMKIIα, in the central AngII pathway, can simply potentiate AngII
response following minipump implantation. Additionally, although CaMKII is
thought to be downstream of the redox mechanisms, few studies have shown
that CaMKII can also activate NOX and increase ROS generation via a positive
feedback mechanism (225). Further studies are also needed to determine if wtCaMKIIα overexpression has any effect on the integrity of the blood brain barrier
which may cause a rapid access of AngII, following subcutaneous infusion, to
certain brain regions that are normally protected by the blood brain barrier.
Based on previous studies demonstrating the Ca2+/CaM independent
sustained CaMKII oxidation in the cardiomyocyte CaMKIIδ isoform (181), we next
generated an adenovirus overexpressing CaMKIIα (mut-AdCaMKIIα) with
mutations in cysteine and methionine at residues 280 and 281 respectively. All
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the CaMKII isoforms except CaMKIIα has paired methionine residues at 281/282
position where as CaMKIIα has a cysteine at the 280 position. Since both
cysteine and methionine are highly susceptible to oxidation because of their low
pKa values, we mutated cysteine to an alanine and the methionine to a valine in
order for CaMKIIα to become resistant to oxidation. To check whether mutation in
these residues interfere with CaMKIIα expression we used Western blot analysis
in CATH.a neurons that were transduced with mut-AdCaMKIIα at different MOIs.
As seen with the wt-CaMKIIα adenovirus, transduction of the mut adenovirus had
a significant overexpression of both total and phosphorylated CaMKIIα protein at
10, 25 and 50 MOI. It should be noted that in order to be consistent with our wtCaMKIIα studies in vitro, we selected the 25MOI of the mutant adenovirus for our
next set of cell culture studies. CaMKIIα gene expression was also detected
using RT-PCR in CATH.a neurons following adenovirus transduction. Similar to
the wild-type adenovirus data, mut-CaMKIIα did not interfere with transcription of
the other CaMKII isoforms. These studies suggest that the mutant CaMKIIα gene
is able to make a functional protein and does not act as a dominant negative
mutation to inhibit the endogenous protein in CATH.a neurons.
We next investigated the effect of mut-CaMKIIα on the AngII-mediated
reduction in K+ current in CATH.a neurons. While our studies with the wtCaMKIIα adenovirus clearly demonstrated that the AngII-mediated inhibition of K+
current was greatly exacerbated in wt-CaMKIIα overexpressing neurons, CATH.a
neurons that were transduced with mut-AdCaMKIIα had similar change in K+
current as the non-transduced and AdEmpty-transduced neurons. These studies
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once again indicate that while in CATH.a neurons CaMKIIα may not be the major
mediator of AngII downstream signaling, however, mutation of the oxidation
susceptible residues of CaMKIIα attenuate the potentiated effects of wt-CaMKIIα
on AngII-regulation of K+ current indicating the importance of CaMKIIα in AngII
intraneuronal signaling.
Our in vivo studies with wt-CaMKIIα suggested that overexpression of
wt-CaMKIIα in the SFO sensitizes mice to an immediate increase in blood
pressure at an initial subpressor dose of subcutaneous AngII. To investigate the
role of mut-CaMKIIα on the chronic AngII-induced hypertensive response, we
injected either ICV AdGFP or mut-AdCaMKIIα prior to AngII minipump
implantation. Interestingly, blood pressure in mice with mut-CaMKIIα went up
immediately after minipump implantation as seen with wt-CaMKIIα
overexpression; however, after 2 days the blood pressure declined and followed
the characteristic AngII-mediated gradual rise in blood pressure as seen in
AdGFP group. The peak change (28 mmHg) in mut-AdCaMKIIα group was
modestly decreased than the AdGFP injected mice. However, the peak increase
in blood pressure was significantly lower in the mut-CaMKIIα mice as compared
to the wt-CaMKIIα overexpressed group. Heart rate did not change between the
groups. The initial rise in blood pressure in the mutant group 1-2 days after AngII
infusion may be explained as a result of the presence of activated
(phosphorylated) CaMKIIα to some extent. It should be noted that although
mutation of the two residues will inhibit oxidation in those specific residues
thereby preventing sustained CaMKIIα activation; however, CaMKIIα can still be
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autophosphorylated in its threonine residue and get activated. Thus, our data
confirm that mutation of the redox-sensitive residues in CaMKIIα leads to the
characteristic gradual increase in blood pressure with slow pressor AngII infusion
with a modest decrease in the peak AngII response as compared with AdGFP
group. Furthermore, mut-CaMKIIα prevents the initial sensitization in mice as
seen with wt-CaMKIIα overexpression.
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Significance of Research
Increasing prevalence of hypertension associated with a high morbidity and
mortality rate is a worldwide epidemic that is persistently rising. As per the World
Health Organization (WHO) an estimated 17 million deaths worldwide each year
are caused by cardiovascular disease, and complications of hypertension
account for 9.4 million of these deaths. In 2012, a report released by the Center
for Disease Control (CDC) stated that within the United States an estimated 67
million Americans have hypertension and of the 47 million people who are
receiving current treatment for hypertension, only 31 million people have their
blood pressure controlled by prescribed medications and/or lifestyle changes.
This alarming statistics indicate that 16 million hypertension patients (34%) are
non-responsive to the current hypertensive therapeutics.
Chronic hypertension results in a myriad of pathologies such as endorgan damage, including vasculature remodeling and dysfunction, cardiac
hypertrophy, thrombosis, fibrosis, nephrosclerosis, atherosclerosis,
neurocognitive disorders, retinopathy, and aneurysm. Since high blood pressure
often has no symptoms, it is left untreated and uncontrolled hypertension is a risk
for several cardiovascular diseases, such as heart failure, stroke, coronary artery
disease, kidney disease, and peripheral vascular disease (5, 235). Currently, the
available antihypertensive prescribed medications are the ones that regulate
renin-angiotensin-aldosterone activity, sympathetic/parasympathetic tone, salt
and water excretion by the kidneys, and the ion channels. One of the common
therapies for cardiovascular diseases is systemic treatment with β-blockers to
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reduce heart rate and blood pressure by blocking the effects of norepinephrine
and epinephrine. However, many of these drugs can cause adverse side effects
including dizziness, headache, insomnia, weakness and fatigue (231). In addition,
a significant population of hypertensive patients is not able to control their high
blood pressure in spite of taking a single or a combination of the above
mentioned drugs.
Numerous studies indicate that cardiovascular diseases, such as
hypertension and heart failure involves activation of the brain renin-angiotensin
system and elevated levels of AngII, the primary effector peptide of the RAS
(203, 204) AngII-intraneuronal signaling involves increased generation of O2which is involved in the regulation of neuronal ion channels, increased neuronal
activation thereby leading to sympathoexcitation and increased blood pressure
(83, 110). We therefore wanted to closely examine the AngII signaling

mechanisms in the neurons in order to identify novel therapeutic targets for
hypertension. Since, CaMKII has been identified previously as an important
mediator of AngII downstream signaling in neurons (80, 81), we propose that
AngII stimulation of neurons induce redox-modification of specific residues in
CaMKIIα which leads to inhibition of K+ channel current and an increase in blood
pressure following AngII infusion in mice.
Although CaMKII has been shown to be redox-sensitive and
susceptible to oxidation in the cardiomyocytes in presence of AngII (181, 187, 220),
the role of AngII in regulation of predominant neuronal isoform of CaMKII
(CaMKIIα) is unknown. To closely examine the role of CaMKIIα in AngII signaling
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in neurons we generated adenoviruses to overexpress both a wild-type form of
CaMKIIα (wt-CaMKIIα) and a mutant CaMKIIα (mut-CaMKIIα) in which specific
redox-sensitive cysteine and methionine residues were mutated. Our studies
suggest that overexpressing the wt-CaMKIIα in neurons exacerbated the AngIImediated inhibition of neuronal K+ current. Additionally, wt-CaMKIIα when
overexpressed in the brain sensitized mice to a significant increase in blood
pressure immediately following AngII infusion. In comparison, mut-CaMKIIα
attenuated the AngII-mediation reduction in K+ current as compared to the wtCaMKIIα and overexpression of mut-CaMKIIα in the brain attenuated the peak
AngII response in a mouse model of AngII hypertension.
Furthermore, our mass spectrometry studies using CATH.a neuronal
cell culture media indicated that a single exogenous administration of AngII (100
nM) is rapidly metabolized within 3 hours in the culture media and should be
replenished every 3 hours to in order to maintain chronically elevated AngII
levels. This is relevant for studies that examine AngII neuronal signaling in vitro
as an attempt to identify mechanisms occurring in patients with hypertension or
heart failure in which levels of AngII is chronically elevated.
In summary, our studies have identified CaMKIIα as a downstream
target of AngII signaling in neurons. More specifically we demonstrated that
mutation of redox-sensitive residues in CaMKIIα can attenuate the potentiated
AngII-response in wt-CaMKIIα overexpressed CATH.a neurons. The AngIIinduced hypertensive response was also attenuated in mice with mut-CaMKIIα
overexpression. Taken together, these studies provide an important insight in the
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redox modifications of CaMKIIα as seen in previous studies with a different
CaMKII isoform. Targeting these residues in CaMKIIα or preventing their
oxidation may therefore identify novel therapeutic targets to treat hypertension or
other diseases in which CaMKIIα is an important player and is susceptible to
oxidation.

Limitations of the study

Although we believe that our studies have advanced the understanding of AngII
signaling in neurons associated with AngII-mediated neurogenic hypertension,
there are certain limitations of this study that we need to consider. One obvious
limitation to our studies is the use of a single in vitro cell culture model. It is
important to highlight that the catecholaminergic CATH.a neuronal cell line used
in this study have been widely identified in the literature as exhibiting similar
AngII-intraneuronal signaling mechanisms as primary neurons isolated from the
hypothalamus and brain stem (14, 79). However, further investigation is needed
with primary neurons isolated from the brains of AngII-infused hypertensive mice
to determine the ROS-mediated CaMKIIα oxidation levels. In addition, neurons
cultured from a variety of cardiovascular brain centers, including the area
postrema, paraventricular nucleus and the rostral ventrolateral medulla, in
addition to the subfornical organ, will also provide important insight into the role
of CaMKIIα in AngII-downstream signaling in those brain regions.
It is also important to consider that the CATH.a neuronal cells were
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cultured in a 21% hyperoxic environment. This is important particularly for our
studies as reactive oxygen species are generated by electron reduction of
molecular oxygen. In addition, neuronal cells in the brain receive about 2-4%
oxygen which is significantly less than the culture environment for CATH.a cells.
An ideal in vitro neuronal cell culture environment for conducting these
experiments would have been in an incubator with 2-4% oxygen and 5% CO2.
A major limitation of the study is that we were not able to differentiate
between the different isoforms of CaMKII in mediating AngII intra-neuronal
signaling. Although we are able to show that CaMKIIα is involved in AngII
signaling and mutating oxidation-sensitive residues of CaMKIIα blunts the
potentiated AngII-mediated blood pressure response and the AngII-induced
decrease in K+ current; however, the involvement of other CaMKII isoforms, such
as CaMKIIβ cannot be overruled. Infact, CATH.a neurons has greater levels of
CaMKIIβ as compared to CaMKIIα as detected by RT-PCR. Future studies are
needed to investigate role of different CaMKII isoforms in mediating AngII
signaling in central neurons.
Another limitation of the study is that we did not perform central acute
AngII injections with ICV mut-CaMKIIα in mice brain. Our wt-CaMKIIα adenovirus
studies indicated that mice with wt-AdCaMKIIα had a greater increase in mean
arterial pressure with central acute AngII injections. It would be interesting to see
if mut-CaMKIIα prevents the increased rise in blood pressure following AngII
injection. If there is still an increase in blood pressure in the mut-AdCaMKIIα
group, that may further confirm our chronic AngII infusion data that the initial rise
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in blood pressure is a result of active phosphorylated CaMKIIα where as the
chronic sustained blood pressure increase is because of CaMKIIα oxidation.

Future Studies

Although we believe our studies have provided important insight in AngII
signaling in central neurons, future studies are required to better understand the
redox regulation of CaMKIIα and its effect on AngII-stimulated central neurons.
One limitation of our studies that needs to be addressed is the identification of
specific residues in CaMKIIα that are important in mediating AngII responses in
neurons. Based on previous studies in a cardiomyocyte isoform of CaMKII (181),
we mutated the cysteine and methionine residues of CaMKIIα at positions 280
and 281 respectively; however, mass spectrometry and proteomics approaches
should be utilized to confirm our findings. Moreover, it would be interesting to see
whether a single residue mutation of either the cysteine or methionine is as
effective as the double mutant. Furthermore, one study has suggested that
CaMKIIα, involved in nitric oxide-induced excitotoxic neuronal cell death,
undergoes S-nitrosylation in two cysteine residues at positions 280 and 289
(189). The study also suggested that mutation of either cysteine abolished the

autonomous activity of CaMKIIα thereby indicating the importance of those two
residues in CaMKIIα activation. It is therefore reasonable to believe that mutating
C289 in addition to our double mutation model may have a greater attenuation of
the AngII-induced increased blood pressure.
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Another important question that needs to be addressed is the role of
specific oxidants in mediating post-translational modifications of CaMKIIα.
Anderson et al. showed that CaMKIIδ undergoes oxidation in the paired
methionine residues in the presence of H2O2 (181). Studies from our lab show that
AngII increased CaMKII phosphorylation in CATH.a neurons and overexpression
of MnSOD attenuates the AngII-mediated CaMKII phosphorylation (83).
Preliminary studies in our lab also suggest that CaMKII oxidation increases within
30 minutes in presence of AngII stimulation; however, the specific role of O2- or
H2O2 in mediating CaMKIIα oxidation is still not clear. Further studies are needed
to overexpress specific ROS scavenging enzyme in order to tease out their role
in AngII-mediated CaMKIIα oxidation. More specifically, experiments should be
done in CATH.a neurons with adenovirus overexpressing superoxide dismutase
(SOD) to scavenge O2- to determine their role in mediating CaMKIIα oxidation.
Since dismutation of O2- generates H2O2, it is important to use a specific H2O2
scavenger such as, catalase or glutathione peroxidase (GPx). Co-transfection of
adenovirus overexpressing SOD and catalase should be utilized to determine
whether the effect is due to scavenging O2- or producing high amounts of H202.
Furthermore, previous reports indicate that AngII stimulation may increase H2O2
levels through NOX activity, monoamine oxidase activity, or from mitochondrial
respiration coupled to endogenous SOD (236, 237). Additionally, since Snitrosylation of CaMKIIα causes autonomous CaMKIIα activity (189), it would be
interesting to see the functional relevance of overexpressing the different
scavenging enzymes on the S-nitrosylation status. Since CaMKII is primarily
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cytoplasmic, investigating the effect of scavenging oxidants in specific subcellular
compartments on CaMKIIα oxidation is also important. Apart from targeting
cytoplasmic ROS mitochondrial targeted SOD and catalase can be utilized to
specifically scavenge mitochondrial O2- and H2O2 and CaMKIIα oxidation levels
can then be measured.
Future studies should also aim at evaluating some of the mechanism
regulating CaMKII oxidation. For example, oxidation of methionine residues leads
to formation of methionine sulfoxide which can be reversed by methionine
sulfoxide reductases (Msr) (176). Infact, methionine sulfoxide reductase A
knockout mouse (MsrA-/-) show increased CaMKIIδ oxidation with AngII and
ishemic stress response (181) However, the role of Msr in AngII intra-neuronal
signaling and AngII-induced hypertensive response is not clear. The expression
levels and activity of these enzymes in cardiovascular regulatory brain nuclei,
such as the subfornical organ in case of AngII-infused hypertensive model is not
known. It would be interesting to see if overexpression of Msr in neurons is able
to prevent the potenetiated AngII-response and the increased blood pressure in
mice.
Studies by Hongpaisan et al. have shown that in hippocampal neurons,
increased mitochondrial O2- activates CaMKII and increases CaMKII kinase
activity (190). They also demonstrated that the increased kinase activity is
mediated at least in part, by suppressing protein phosphatases, such as PP1 and
PP2A. Since CaMKII is classically activated by autophosphorylation in Thr 286
(Thr 287 in other CaMKII isoforms) protein phosphatases play a crucial role in
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deactivating CaMKII by dephosphorylating the threonine residue. In our
preliminary studies we found that AngII inhibits PP2A activity in CATH.a neurons
without affecting PP2A protein expression. Western blot analysis for all three
subunits of PP2A demonstrated that AngII does not change protein expression of
PP2A subunits. However, overexpression of MnSOD to inhibit mitochondrial O2attenuates the AngII-mediated decrease in PP2A activity. Since, protein
phosphatases are also known to be redox-sensitive (179, 180), future studies are
needed to determine ROS-mediated PP2A modification which might explain the
AngII-induced decrease in PP2A activity.
Our studies elucidated that overexpression of wt-CaMKIIα
exacerbates the AngII-mediated inhibition of K+ current in CATH.a neurons. In
addition the mut-CaMKIIα is capable of attenuating the potentiated AngII
response in wt-CaMKIIα transduced neurons. Although the RT-PCR data for the
different voltage-gated K+ channels show that wt-CaMKIIα overexpression
increases the basal expression of these Kv channels, further studies must be
done to determine their protein expression in addition to cellular localization.
Among the several targets of CaMKII, one of the important target are the ion
channels and so direct regulation of Kv channels by CaMKIIα could be assessed
in CATH.a neurons. Co-immunoprecipitation experiments could ascertain if
CaMKIIα directly interacts with Kv channels and phosphorylates them. It was
previously reported that AngII downregulates Kv4.3 in CATH.a neurons and also in
the RVLM of rats with chronic heart failure (85). It is therefore important to
determine whether the AngII-mediated downregulation of Kv4.3 along with the
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other Kv channels is attenuated with mut-CaMKIIα overexpression.
Additionally, one of the most exciting future experiments would be to
identify other proteins that are modulated by O2- in presence of AngII. ROS are
known to regulate a number of proteins by modifying their amino acid residues
within their active sites. An exciting future investigation would be to determine
whether ROS can directly act on ion channels to post-translationally modify them
and regulate the flow of ions. It is known that in neurons H2O2 accelerates the
Ca2+ channel opening in the plasma membrane by oxidizing certain subunits
within the channel complex. Studies by Zimmerman et al. have demonstrated
that the AngII-mediated O2- is involved in the increased influx of extracellular
Ca2+ through voltage-gated Ca2+ channels (84). It is therefore important to know
whether O2- or H2O2 play a direct regulation of either the Ca2+ or the K+ channels
in neuronal cells. Furthermore, Sumners and colleagues have clearly identified
PKC as a downstream mediator of AngII signaling in neurons (14, 79). Since
PKCs are also Ca2+ dependent enzymes and have active site cysteines it is
reasonable to believe that PKCs are susceptible to ROS-mediated oxidation. In
fact reports have previously shown that in different cell types ROS can act either
upstream or downstream of PKCs thereby amplifying the response. For example,
PKC can activate NADPH oxidase thus increasing the generation of ROS which
in turn activate and regulate PKC function (238). These are exciting and critical
studies that will build upon the novel findings of our studies.
In addition to ROS, reactive nitrogen species (RNS) has also received
considerable attention in the past years regarding their role on the cardiovascular
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system. Nitric oxide (NO) plays an important role in cardiovascular regulation by
causing vasodilation in the periphery. In the cardiovascular regulatory regions of
the brain, NO acts through a GABA-dependent mechanism to induce sympathoinhibition that decreases blood pressure and heart rate (239). In a diffusion-limited
reaction O2- has the ability to quench endogenous NO and form peroxynitrite
(OONO-) thereby reducing NO bioavailability. As opposed to NO, OONO- is
considered to be a toxic and powerful oxidant with known pathological
consequences (240, 241). ONOO- is also potent in causing irreversible protein
nitration thereby changing the biological function of the target protein. Hence, the
role of ONOO- on CaMKIIα or other downstream molecules of AngII-signaling
could reveal other possible redox modifications of those proteins. Therefore
unraveling these AngII-redox mechanisms within the CNS will be crucial studies
to pursue.
Additional research is also needed to determine the role of reactive
carbonyl species (RCS) on CaMKIIα and other downstream targets of AngIIintraneuronal signaling and their subsequent involvement in neurocardiovascular diseases. Reactive carbonyl species, such as acrolein,
methylglyoxyl, malondialdehyde, 3-deoxyglucosome, and 4-hydroxy-2-alkenals,
are small diffusible aldehydes or ketones that are generated from oxidation of
lipids, glucose, and amino acids. Although the importance of RCS in
cardiovascular disease is unclear, it may be possible that the RCS act as the
primary mediators of dysfunction and damage (242-245) whereas ROS are the
secondary mediators. This might explain why many clinical trials with
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antioxidants trying to target the ROS have failed. In future studies, we could
overexpress glutathione S-transferases, aldose reductase, aldehyde
dehydrodenase, and glyoxylases to degrade RCS and determine their functional
relevance in mediating post-translational modifications of CaMKIIα or other
downstream signaling molecule of AngII in central neurons.
In summary, we believe that our studies have demonstrated the
importance of CaMKIIα in mediating AngII-signaling in neurons and the AngIIinduced hypertension. Importantly, our studies have opened the door for an
extensive series of both in vivo and in vitro future experiments designed to
better understand the role of redox-sensitive proteins in central AngII signaling.
In performing these additional studies, it is our hope that novel therapeutics will
be developed to treat AngII-dependent cardiovascular diseases, including
hypertension.
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